Share:
Biotech Showcase™ 2013 Presenting Companies
Click on any row to see more company information
13therapeutics
Country: United States
Country: United States
13therapeutics, a spinout from Oregon Health and Science University, has a patented portfolio of anti-inflammatory peptides. It is moving its lead peptide forward for the TOP...
Share this:
13therapeutics
13therapeutics is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 4:30 pm. Room Mission I.
Wednesday, January 9 at 4:30 pm. Room Mission I.
13therapeutics, a spinout from Oregon Health and Science University, has a patented portfolio of anti-inflammatory peptides. It is moving its lead peptide forward for the TOPICAL treatment of hearing disorders, Noise Induced Hearing Loss, Age Related Hearing loss, Otitis Media, and Ototoxic Hearing Loss, markets with no current therapeutics.
Biotech Showcase™ 2013
4P Therapeutics
Country: United States
Country: United States
4P Therapeutics is focused on research and development of novel drug delivery technologies. 4P Therapeutics is developing novel pharmaceutical products in collaboration with...
Share this:
4P Therapeutics
4P Therapeutics is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 10:30 am. Room Hearst.
Monday, January 7 at 10:30 am. Room Hearst.
4P Therapeutics is focused on research and development of novel drug delivery technologies. 4P Therapeutics is developing novel pharmaceutical products in collaboration with leading pharmaceutical and medical device companies. In addition, 4P Therapeutics is also developing its own proprietary products.
Visit: http://4ptherapeutics.com
Biotech Showcase™ 2013
Ability Pharmaceuticals
Country: Spain
Country: Spain
Ability has developed a new proprietary drug class called Lipid Analogue Therapeutics. It has two drug candidates in development in several cancer types. Its first candidate...
Share this:
Ability Pharmaceuticals
Ability Pharmaceuticals is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 4:15 pm. Room Mission I.
Tuesday, January 8 at 4:15 pm. Room Mission I.
Ability has developed a new proprietary drug class called Lipid Analogue Therapeutics. It has two drug candidates in development in several cancer types. Its first candidate will begin Phase 1B trials in 2Q for lung and pancreatic cancer. Ability’s business model is to develop candidates through POC.
Visit: http://www.abilitypharma.com
Biotech Showcase™ 2013
Actinium Pharmaceuticals
Country: United States
Country: United States
Actinium uses antibody directed targeted payload therapies to meet unmet medical needs in certain types of cancers. Its lead product is an Iodine 131 directed isotope using t...
Share this:
Actinium Pharmaceuticals
Actinium Pharmaceuticals is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 11:45 am. Room Mission I.
Monday, January 7 at 11:45 am. Room Mission I.
Actinium uses antibody directed targeted payload therapies to meet unmet medical needs in certain types of cancers. Its lead product is an Iodine 131 directed isotope using the antibody BC8 which targets CD45. This product is ready for Phase III in relapsed and refractory AML patients.
Biotech Showcase™ 2013
ActoGeniX
Country: Belgium
Country: Belgium
ActoGeniX isfocused on the development and commercialization of ActoBiotics™, a novel class of orally available biopharmaceuticals for the treatment of GI, mucosal and immun...
Share this:
ActoGeniX
ActoGeniX is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 4:15 pm. Room Mission I .
Monday, January 7 at 4:15 pm. Room Mission I .
ActoGeniX isfocused on the development and commercialization of ActoBiotics™, a novel class of orally available biopharmaceuticals for the treatment of GI, mucosal and immunological diseases. ActoBiotics™ are safe, efficacious, and with low cost of goods compa red to standard injectable biologicals. ActoGeniX recently entered into an agreement with Merck.
Visit: http://www.actogenix.com
Biotech Showcase™ 2013
Adaptimmune
Country: United Kingdom
Country: United Kingdom
Adaptimmune’s mission is to develop disruptive therapy for serious disease using engineered T cells. The Company’s core technology is the development of affinity enhanceme...
Share this:
Adaptimmune
Adaptimmune is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 10:00 am. Room Hearst.
Monday, January 7 at 10:00 am. Room Hearst.
Adaptimmune’s mission is to develop disruptive therapy for serious disease using engineered T cells. The Company’s core technology is the development of affinity enhancement of T cell receptors (TCR) for use in adoptive T cell therapy.
Visit: http://adaptimmune.com
Biotech Showcase™ 2013
Addex Therapeutics
(PINK:ADDXF)
Country: Switzerland
(PINK:ADDXF)
Country: Switzerland
Addex Therapeutics is pioneering discovery and development of an emerging class of oral small molecule drugs, called allosteric modulators, which can be exquisitely selective ...
Share this:
Addex Therapeutics
Addex Therapeutics is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 4:45 pm. Room Mission II.
Monday, January 7 at 4:45 pm. Room Mission II.
Addex Therapeutics is pioneering discovery and development of an emerging class of oral small molecule drugs, called allosteric modulators, which can be exquisitely selective for their intended target and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs.
Biotech Showcase™ 2013
Aderans Research
Country: United States
Country: United States
The Aderans is the research arm of two leading hair restoration companies. It is pioneering a method of cellular hair regeneration referred to as the Ji Gami™ process. By re...
Share this:
Aderans Research
Aderans Research is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 3:45 pm. Room Hearst.
Wednesday, January 9 at 3:45 pm. Room Hearst.
Track: Track A
Country: United States
Ownership: PRIVATE
Country: United States
Ownership: PRIVATE
The Aderans is the research arm of two leading hair restoration companies. It is pioneering a method of cellular hair regeneration referred to as the Ji Gami™ process. By rejuvenating hair-producing follicles, hair regeneration can generate an unlimited number of hairs from an individual's own hair cells.
Biotech Showcase™ 2013
ADOCIA
(EPA:ADOC)
Country: France
(EPA:ADOC)
Country: France
Adocia is specialsed in insulin therapy and the treatment of diabetic foot. Through its BioChaperone state-of-art technological platform, Adocia enhances the effectiveness and...
Share this:
ADOCIA
ADOCIA is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 11:00 am. Room Mission II.
Monday, January 7 at 11:00 am. Room Mission II.
Adocia is specialsed in insulin therapy and the treatment of diabetic foot. Through its BioChaperone state-of-art technological platform, Adocia enhances the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these therapies broadly accessible.
Visit: http://www.adocia.com
Biotech Showcase™ 2013
Advanced Cell Technology
(OTCBB:ACTC)
Country: United States
(OTCBB:ACTC)
Country: United States
Advanced Cell Technology is conducting three human embryonic stem cell (hESC)-based clinical trials in the US and EU. ACT has a patented “embryo-safe” technique for derivi...
Share this:
Advanced Cell Technology
Advanced Cell Technology is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 10:00 am. Room Powell.
Tuesday, January 8 at 10:00 am. Room Powell.
Advanced Cell Technology is conducting three human embryonic stem cell (hESC)-based clinical trials in the US and EU. ACT has a patented “embryo-safe” technique for deriving hESCs without harm to embryos, and is also focused on its Hemangioblast platform and its mesenchymal stem cell program.
Visit: http://www.advancedcell.com
Biotech Showcase™ 2013
Aethlon Medical, Inc.
(OTCBB:AEMD)
Country: United States
(OTCBB:AEMD)
Country: United States
Aethlon Medical’s ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices that improve the benefit of drug therapies throu...
Share this:
Aethlon Medical, Inc.
Aethlon Medical, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 4:45 pm. Room Powell.
Tuesday, January 8 at 4:45 pm. Room Powell.
Aethlon Medical’s ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices that improve the benefit of drug therapies through the rapid, yet selective clearance of disease enabling particles from the entire circulatory system.
Biotech Showcase™ 2013
Affimed Therapeutics AG
Country: Germany
Country: Germany
Affimed has two products in development in lymphoma indications that will reach inflection points in 2014 with significant benchmark valuations. The key to Affimed’s technol...
Share this:
Affimed Therapeutics AG
Affimed Therapeutics AG is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 2:45 pm. Room Hearst.
Monday, January 7 at 2:45 pm. Room Hearst.
Affimed has two products in development in lymphoma indications that will reach inflection points in 2014 with significant benchmark valuations. The key to Affimed’s technology is the TandAb platform enabling the generation of antibody therapeutics with improved efficacy and a promising safety profile.
Visit: http://affimed.com
Biotech Showcase™ 2013
AiCuris GmbH & Co. KG
Country: Germany
Country: Germany
AiCuris is focused on the discovery, research and clinical development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potenti...
Share this:
AiCuris GmbH & Co. KG
AiCuris GmbH & Co. KG is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 9:00 am. Room Mission I.
Wednesday, January 9 at 9:00 am. Room Mission I.
AiCuris is focused on the discovery, research and clinical development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. As AiCuris is dedicated to innovation in the field of anti-infective drugs, its compounds are resistance-breaking by design.
Visit: http://aicuris.com
Biotech Showcase™ 2013
Allied Healthcare Group
(ASX:AHZ)
Country: Australia
(ASX:AHZ)
Country: Australia
Allied is a diversified healthcare company focused developing next generation technologies with world class partners. The Company has programs in regenerative medicine and vac...
Share this:
Allied Healthcare Group
Allied Healthcare Group is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 11:30 am. Room Powell.
Wednesday, January 9 at 11:30 am. Room Powell.
Allied is a diversified healthcare company focused developing next generation technologies with world class partners. The Company has programs in regenerative medicine and vaccines with revenues from its existing profitable medical sales and distribution business and $7M in revenues with its leading product CardioCel® scheduled for globally approval in 2013.
Biotech Showcase™ 2013
Alliqua Inc.
(PINK:ALQA)
Country: United States
(PINK:ALQA)
Country: United States
Alliqua currently markets its own proprietary brands of wound dressings: SilverSeal® Hydrogel, an antimicrobial dressing; and Hydress® a moist wound dressing. We intend to ...
Share this:
Alliqua Inc.
Alliqua Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 4:45 pm. Room Powell.
Monday, January 7 at 4:45 pm. Room Powell.
Alliqua currently markets its own proprietary brands of wound dressings: SilverSeal® Hydrogel, an antimicrobial dressing; and Hydress® a moist wound dressing. We intend to pursue projects in the fields of active ingredient and transdermal drug delivery, as well as advanced wound care.
Visit: http://www.alliqua.com
Biotech Showcase™ 2013
AlphaCore Pharma
Country: United States
Country: United States
AlphaCore develops recombinant human lecithin cholesterol acyltransferase (rhLCAT) as a novel therapeutic agent for the treatment of high risk atherosclerosis and serious lipi...
Share this:
AlphaCore Pharma
AlphaCore Pharma is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 3:00 pm. Room Mission I.
Tuesday, January 8 at 3:00 pm. Room Mission I.
AlphaCore develops recombinant human lecithin cholesterol acyltransferase (rhLCAT) as a novel therapeutic agent for the treatment of high risk atherosclerosis and serious lipid metabolism disorders. Its lead candidate is under development as enzyme replacement therapy for the treatment of familial LCAT deficiency with orphan designations in the US and EU.
Biotech Showcase™ 2013
ALS Biopharma, LLC
Country: United States
Country: United States
ALS Biopharma, in collaboration with Fox Chase Chemical Diversity Center and Rutgers University, has discovered a prodrug of the approved-drug riluzole which has significantly...
Share this:
ALS Biopharma, LLC
ALS Biopharma, LLC is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 11:00 am. Room Hearst.
Tuesday, January 8 at 11:00 am. Room Hearst.
ALS Biopharma, in collaboration with Fox Chase Chemical Diversity Center and Rutgers University, has discovered a prodrug of the approved-drug riluzole which has significantly improved pharmacokinetic properties, including the lack of the variable Cyp1A2 metabolism that causes very large patient-to-patient variability for the use of riluzole itself.
Visit: http://alsbiopharma.com
Biotech Showcase™ 2013
Amarantus Bioscience, Inc.
(OTCBB:AMBS)
Country: United States
(OTCBB:AMBS)
Country: United States
Amarantus, a development-stage company, is focused on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or d...
Share this:
Amarantus Bioscience, Inc.
Amarantus Bioscience, Inc. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 9:00 am. Room Powell.
Wednesday, January 9 at 9:00 am. Room Powell.
Amarantus, a development-stage company, is focused on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s disease, Traumatic Brain Injury and other human diseases.
Visit: http://www.amarantus.com
Biotech Showcase™ 2013
America Stem Cell Inc
Country: United States
Country: United States
America Stem Cell is engaged in the development of stem cell enabling technologies and the key technology platforms -- ASC-101 and ASC-201 -- are designed to improve the engra...
Share this:
America Stem Cell Inc
America Stem Cell Inc is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 3:00 pm. Room Mission I.
Wednesday, January 9 at 3:00 pm. Room Mission I.
America Stem Cell is engaged in the development of stem cell enabling technologies and the key technology platforms -- ASC-101 and ASC-201 -- are designed to improve the engraftment of stem cells to target organs and increase their therapeutic potential.
Visit: http://americastemcell.com
Biotech Showcase™ 2013
Amerigen Pharmaceuticals
Country: United States
Country: United States
Amerigen is uniquely positioned to introduce high quality and affordable medicines into both the American and Chinese markets utilizing its western systems of management, qual...
Share this:
Amerigen Pharmaceuticals
Amerigen Pharmaceuticals is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 10:45 am. Room Hearst.
Monday, January 7 at 10:45 am. Room Hearst.
Amerigen is uniquely positioned to introduce high quality and affordable medicines into both the American and Chinese markets utilizing its western systems of management, quality assurance and control, along with our manufacturing site approvals from the US FDA and Chinese SFDA.
Biotech Showcase™ 2013
Amicrobe, Inc.
Country: United States
Country: United States
Amicrobe is currently developing two product candidates: Amicrobe AB-100rL Anti-Infective and Amicrobe Wound & Burn Gel. A-Block-based product candidates can act as both an an...
Share this:
Amicrobe, Inc.
Amicrobe, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 4:45 pm. Room Mission I.
Monday, January 7 at 4:45 pm. Room Mission I.
Amicrobe is currently developing two product candidates: Amicrobe AB-100rL Anti-Infective and Amicrobe Wound & Burn Gel. A-Block-based product candidates can act as both an antimicrobial therapeutic to treat and antimicrobial barrier to prevent, thereby providing a more effective approach to a large and growing unmet need.
Visit: http://www.amicrobe.com
Biotech Showcase™ 2013
Amorcyte
(NYSEAMEX:NBS)
Country: United States
(NYSEAMEX:NBS)
Country: United States
Amorcyte, a NeoStem company, develops cell therapy products to treat cardiovascular disease. Amorcyte will be provided with a pharmaceutical grade cGMP manufactured product th...
Share this:
Amorcyte
Amorcyte is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 4:15 pm. Room Powell.
Tuesday, January 8 at 4:15 pm. Room Powell.
Amorcyte, a NeoStem company, develops cell therapy products to treat cardiovascular disease. Amorcyte will be provided with a pharmaceutical grade cGMP manufactured product that can be distributed commercially by Progenitor Cell Therapy, another NeoStem company and a leading provider of clinical, manufacturing and other services for the cell therapy industry.
Visit: http://www.amorcyte.com/
Biotech Showcase™ 2013
Amorfix Life Sciences Limited
(TSE:AMF)
Country: Canada
(TSE:AMF)
Country: Canada
Amorfix Life Sciences is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheime...
Share this:
Amorfix Life Sciences Limited
Amorfix Life Sciences Limited is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 9:30 am. Room Powell.
Tuesday, January 8 at 9:30 am. Room Powell.
Amorfix Life Sciences is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheimer's Disease.
Visit: http://www.amorfix.com/
Biotech Showcase™ 2013
AmpliPhi Biosciences
(PINK:APHB)
(PINK:APHB)
AmpliPhi, dedicated to the development of innovative antibacterial solutions to improve human and animal health through the application of its proprietary bacteriophage platfo...
Share this:
AmpliPhi Biosciences
AmpliPhi Biosciences is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 1:45 pm. Room Powell.
Wednesday, January 9 at 1:45 pm. Room Powell.
AmpliPhi, dedicated to the development of innovative antibacterial solutions to improve human and animal health through the application of its proprietary bacteriophage platform, lead product development programs are targeting gram-negative infections that are often resistant to existing antibiotic treatments.
Visit: http://www.ampliphibio.com
Biotech Showcase™ 2013
ANERGIS SA
Country: Switzerland
Country: Switzerland
Anergis develops proprietary breakthrough allergy vaccines that provide safe and ultra-fast allergen specific immunotherapy (SIT) in two months instead of the standard three y...
Share this:
ANERGIS SA
ANERGIS SA is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 11:00 am. Room Hearst.
Monday, January 7 at 11:00 am. Room Hearst.
Anergis develops proprietary breakthrough allergy vaccines that provide safe and ultra-fast allergen specific immunotherapy (SIT) in two months instead of the standard three years, based on its Contiguous Overlapping Peptides (COP) technology.
Visit: http://anergis.ch
Biotech Showcase™ 2013
Applied Integrin Sciences, Inc.
Country: United States
Country: United States
Applied Integrin Sciences is committed to discover, develop and commercialize protein drug therapies for cancer treatments that reduce solid tumor growth and progression and i...
Share this:
Applied Integrin Sciences, Inc.
Applied Integrin Sciences, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 2:00 pm. Room Hearst.
Tuesday, January 8 at 2:00 pm. Room Hearst.
Track: Track A
Country: United States
Ownership: PRIVATE
Country: United States
Ownership: PRIVATE
Applied Integrin Sciences is committed to discover, develop and commercialize protein drug therapies for cancer treatments that reduce solid tumor growth and progression and improve patient survival and quality of life.
Visit: http://www.integrins.com
Biotech Showcase™ 2013
Aradigm Corporation
(OTCBB:ARDM)
(OTCBB:ARDM)
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of s...
Share this:
Aradigm Corporation
Aradigm Corporation is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 11:00 am. Room Powell.
Wednesday, January 9 at 11:00 am. Room Powell.
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include development programs addressing the treatments of bronchiectasis, cystic fibrosis, inhaled tularemia and anthrax infections and smoking cessation. In selecting our proprietary development programs, we primarily seek drugs approved by the United States Food and Drug Administration that can be reformulated for both existing and new indications in respiratory diseases. Our intent is to use our pulmonary delivery methods and formulations to improve their safety, efficacy and convenience of administration to patients.
Visit: http://www.aradigm.com
Biotech Showcase™ 2013
Aratana Therapeutics
Country: United States
Country: United States
Aratana is uniquely positioned to deliver new, high-quality medicines to address unmet needs in companion animal care. Our competitive advantage resides in our ability to iden...
Share this:
Aratana Therapeutics
Aratana Therapeutics is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 5:00 pm. Room Hearst.
Tuesday, January 8 at 5:00 pm. Room Hearst.
Aratana is uniquely positioned to deliver new, high-quality medicines to address unmet needs in companion animal care. Our competitive advantage resides in our ability to identify, acquire and develop high-value commercial products for companion animals in a cost effective and efficient manner.
Visit: http://www.aratanarx.com
Biotech Showcase™ 2013
arGEN-X BV
Country: Netherlands
Country: Netherlands
arGEN-X's proprietary antibody platforms deliver gold standard, human therapeutic antibodies which blanket complex targets with an unprecedented diversity of functional antibo...
Share this:
arGEN-X BV
arGEN-X BV is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 9:15 am. Room Mission I.
Monday, January 7 at 9:15 am. Room Mission I.
arGEN-X's proprietary antibody platforms deliver gold standard, human therapeutic antibodies which blanket complex targets with an unprecedented diversity of functional antibodies. arGEN-X creates and develops a portfolio of therapeutic antibodies alone and in collaboration with partners. Its activities span discovery till clinical PoC.
Visit: http://argen-x.com
Biotech Showcase™ 2013
AssureRx Health
Country: United States
Country: United States
AssureRx is a personalized medicine company dedicated to helping clinicians determine the right drug for individual patients suffering from medical conditions. Its proprietary...
Share this:
AssureRx Health
AssureRx Health is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 3:15 pm. Room Mission I.
Monday, January 7 at 3:15 pm. Room Mission I.
AssureRx is a personalized medicine company dedicated to helping clinicians determine the right drug for individual patients suffering from medical conditions. Its proprietary technology is based on pharmacogenomics as well as evidence-based medicine and clinical pharmacology.
Biotech Showcase™ 2013
Astex Pharmaceuticals, Inc.
(NASDAQ:ASTX)
Country: United States
(NASDAQ:ASTX)
Country: United States
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pip...
Share this:
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 2:45 pm. Room Mission II.
Wednesday, January 9 at 2:45 pm. Room Mission II.
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies.
Visit: http://astx.com
Biotech Showcase™ 2013
Athersys, Inc.
(NASDAQ:ATHX)
Country: United States
(NASDAQ:ATHX)
Country: United States
Athersys, a clinical stage company, is engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. It ...
Share this:
Athersys, Inc.
Athersys, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 3:15 pm. Room Powell.
Tuesday, January 8 at 3:15 pm. Room Powell.
Athersys, a clinical stage company, is engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. It is developing its MultiStem® cell therapy product, adult-derived "off-the-shelf" stem cell product platform for indications in cardiovascular, neurological, inflammatory and immune disease.
Visit: http://www.athersys.com/
Biotech Showcase™ 2013
Atossa Genetics, Inc.
(NASDAQ:ATOS)
Country: United States
(NASDAQ:ATOS)
Country: United States
Atossa is committed to prevent breast cancer through the application of patented, FDA-cleared products and services to identify and treat women at high risk.
Share this:
Atossa Genetics, Inc.
Atossa Genetics, Inc. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 10:00 am. Room Powell.
Wednesday, January 9 at 10:00 am. Room Powell.
Atossa is committed to prevent breast cancer through the application of patented, FDA-cleared products and services to identify and treat women at high risk.
Biotech Showcase™ 2013
Avita Medical
(ASX:AVH)
Country: United States
(ASX:AVH)
Country: United States
Avita develops and distributes regenerative and tissue‐engineered products for the treatment of wounds, scars and skin defects. Its lead product, ReCell® Spray‐On ...
Share this:
Avita Medical
Avita Medical is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 10:00 am. Room Mission II.
Tuesday, January 8 at 10:00 am. Room Mission II.
Avita develops and distributes regenerative and tissue‐engineered products for the treatment of wounds, scars and skin defects. Its lead product, ReCell® Spray‐On Skin™, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. It is patented, CE‐marked, TGA‐registered in Australia, and SFDA‐cleared in China.
Visit: http://www.avitamedical.com/
Biotech Showcase™ 2013
Axerion Therapeutics
Country: United States
Country: United States
Axerion is developing disease-modifying therapeutics for the management and treatment of spinal cord injury (SCI), stroke recovery and Alzheimer's Disease. Its Prion Protein ...
Share this:
Axerion Therapeutics
Axerion Therapeutics is scheduled to present at Biotech Showcase™ 2013
Wednesday , January 9 at 9:00 am. Room Hearst.
Wednesday , January 9 at 9:00 am. Room Hearst.
Axerion is developing disease-modifying therapeutics for the management and treatment of spinal cord injury (SCI), stroke recovery and Alzheimer's Disease. Its Prion Protein project, a novel potential therapeutic approach for Alzheimer’s, may prevent a cascade of events that result in brain dysfunction.
Biotech Showcase™ 2013
Bavarian Nordic A/S
(CPH:BAVA)
Country: Denmark
(CPH:BAVA)
Country: Denmark
Bavarian Nordic, a vaccine-focused company, with eight development programs targeting cancer and infectious diseases. Its lead program is a therapeutic vaccine candidate for ...
Share this:
Bavarian Nordic A/S
Bavarian Nordic A/S is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 11:30 am. Room Mission II.
Monday, January 7 at 11:30 am. Room Mission II.
Bavarian Nordic, a vaccine-focused company, with eight development programs targeting cancer and infectious diseases. Its lead program is a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer Institute.
Biotech Showcase™ 2013
Bio-Path Holdings, Inc.
(PINK:BPTH)
Country: United States
(PINK:BPTH)
Country: United States
Bio-Path is focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughou...
Share this:
Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 11:00 am. Room Mission II.
Tuesday, January 8 at 11:00 am. Room Mission II.
Bio-Path is focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers.
Visit: http://biopathholdings.com
Biotech Showcase™ 2013
BioAxone BioSciences
Country: United States
Country: United States
BioAxone's Cethrin is a biologic drug that is a transformative treatment for spinal cord injury. A Phase II clinical study showed very promising signs of profound recovery in ...
Share this:
BioAxone BioSciences
BioAxone BioSciences is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 9:15 am. Room Hearst.
Wednesday, January 9 at 9:15 am. Room Hearst.
BioAxone's Cethrin is a biologic drug that is a transformative treatment for spinal cord injury. A Phase II clinical study showed very promising signs of profound recovery in patients with cervical injury. Cethrin could be approved in as little as 3 years with $15M.
Visit: http://www.bioaxonebio.com
Biotech Showcase™ 2013
BioBehavioral Diagnostics Company
Country: United States
Country: United States
BioBehavioral manufactures and markets the Quotient™ ADHD System, a tool that aids in the objective and accurate assessment of ADHD symptoms. The firm’s vision is to provi...
Share this:
BioBehavioral Diagnostics Company
BioBehavioral Diagnostics Company is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 2:15 pm. Room Hearst.
Tuesday, January 8 at 2:15 pm. Room Hearst.
BioBehavioral manufactures and markets the Quotient™ ADHD System, a tool that aids in the objective and accurate assessment of ADHD symptoms. The firm’s vision is to provide accurate tools for the diagnosis and management of neurological and psychiatric conditions, leading to a transformation of behavioral medicine.
Visit: http://biobdx.com
Biotech Showcase™ 2013
Biodesix
Country: United States
Country: United States
Biodesix is a personalized medicine company focused on the development of diagnostic products that inform treatment decisions and improve patient care. In 2009, Biodesix laun...
Share this:
Biodesix
Biodesix is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 3:30 pm. Room Mission I.
Wednesday, January 9 at 3:30 pm. Room Mission I.
Biodesix is a personalized medicine company focused on the development of diagnostic products that inform treatment decisions and improve patient care. In 2009, Biodesix launched VeriStrat®, a serum-based proteomic test to help physicians guide treatment for patients with non-small cell lung cancer. VeriStrat is based on ProTS®, proprietary technology which harnesses the power of mass spectrometry and enables the discovery of specific molecular profiles that characterize a patient’s condition or likely outcome in response to therapy. The ProTS® platform has broad application and provides the foundation for collaborations with leading researchers as well as partnerships with biotechnology and pharmaceutical companies seeking to develop companion diagnostics and improve the targeting of their therapies.
Visit: http://www.biodesix.com
Biotech Showcase™ 2013
Bioniche Life Sciences Inc.
(TSE:BNC)
Country: Canada
(TSE:BNC)
Country: Canada
Bioniche generates ~$30M in annual revenues from animal health product sales, developed the world’s first fully registered E. coli O157 cattle vaccine, and has a bladder can...
Share this:
Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 1:45 pm. Room Mission II.
Wednesday, January 9 at 1:45 pm. Room Mission II.
Bioniche generates ~$30M in annual revenues from animal health product sales, developed the world’s first fully registered E. coli O157 cattle vaccine, and has a bladder cancer therapy in Phase III clinical testing. The underlying mycobacterial cell wall technology may have applicability in other human therapies.
Visit: http://www.bioniche.com
Biotech Showcase™ 2013
Bionomics
(ASX:BNO)
Country: Australia
(ASX:BNO)
Country: Australia
Bionomics discovers and develops innovative
therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in t...
Share this:
Bionomics
Bionomics is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 10:30 am. Room Powell.
Monday, January 7 at 10:30 am. Room Powell.
Bionomics discovers and develops innovative
therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis.
Visit: http://bionomics.com.au
Biotech Showcase™ 2013
Bionure Farma, S.L.
Country: Spain
Country: Spain
Bionure is focuses its activity in neurodegeneration and neuroprotection and develops neuroprotective drugs for multiple sclerosis and other neurological and ophthalmological ...
Share this:
Bionure Farma, S.L.
Bionure Farma, S.L. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 2:00 pm. Room Mission I.
Wednesday, January 9 at 2:00 pm. Room Mission I.
Bionure is focuses its activity in neurodegeneration and neuroprotection and develops neuroprotective drugs for multiple sclerosis and other neurological and ophthalmological diseases such as glaucoma.
Visit: http://www.bionure.com
Biotech Showcase™ 2013
Blend Therapeutics
Country: United States
Country: United States
Blend is advancing a distinctive class of innovative oncology compounds based on its new chemical entity (NCE) drug discovery engine and patented nanotechnology. Blend’s dr...
Share this:
Blend Therapeutics
Blend Therapeutics is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 10:00 am. Room Hearst.
Wednesday, January 9 at 10:00 am. Room Hearst.
Blend is advancing a distinctive class of innovative oncology compounds based on its new chemical entity (NCE) drug discovery engine and patented nanotechnology. Blend’s drug discovery efforts have been highly productive in generating entirely new classes of platinum drugs, as well as other proprietary NCEs for oncology.
Visit: http://www.blendtx.com/
Biotech Showcase™ 2013
Capricor, Inc.
Country: United States
Country: United States
Capricor’s cardiac-derived stem cells (CDCs) represent a novel treatment to repair the heart after muscle loss following large heart attacks. This is accomplished through th...
Share this:
Capricor, Inc.
Capricor, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 10:15 am. Room Mission I.
Tuesday, January 8 at 10:15 am. Room Mission I.
Capricor’s cardiac-derived stem cells (CDCs) represent a novel treatment to repair the heart after muscle loss following large heart attacks. This is accomplished through the regeneration of heart muscle and the shrinking of scar tissue.
Visit: http://www.capricor.com
Biotech Showcase™ 2013
Cardium Therapeutics
(NYSEAMEX:CXM)
Country: United States
(NYSEAMEX:CXM)
Country: United States
Cardium is a health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to...
Share this:
Cardium Therapeutics
Cardium Therapeutics is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 2:15 pm. Room Powell.
Monday, January 7 at 2:15 pm. Room Powell.
Cardium is a health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet needs and with pathways to commercialization, partnering and other monetization. Cardium's portfolio includes Tissue Repair Company, Cardium Biologics, and To Go Brands.
Visit: http://cardiumthx.com
Biotech Showcase™ 2013
Cerecor Inc.
Country: United States
Country: United States
Cerecor Inc is focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Founded in A...
Share this:
Cerecor Inc.
Cerecor Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 9:00 am. Room Hearst.
Monday, January 7 at 9:00 am. Room Hearst.
Cerecor Inc is focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Founded in April 2011, it has a management team with deep experience in drug development.
Visit: http://cerecor.com
Biotech Showcase™ 2013
Cipher Pharmaceuticals
(TSE:DND)
Country: Canada
(TSE:DND)
Country: Canada
Cipher is a specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules. Cipher's strategy is to in-license clearly dif...
Share this:
Cipher Pharmaceuticals
Cipher Pharmaceuticals is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 1:45 pm. Room Powell.
Monday, January 7 at 1:45 pm. Room Powell.
Cipher is a specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules. Cipher's strategy is to in-license clearly differentiated products, advance them through the clinical development and regulatory approval stages, and out-license to international marketing partners. Cipher has successfully commercialized three products (Lipofen, ConZip and Absorica).
Visit: http://www.cipherpharma.com
Biotech Showcase™ 2013
Circadian Technologies Limited
(ASX:CIR)
Country: Australia
(ASX:CIR)
Country: Australia
Circadian an emerging leader in the field of angiogenesis-based treatments for cancer. Focusing on a class of drug targets called Vascular Endothelial Growth Factors (VEGFs), ...
Share this:
Circadian Technologies Limited
Circadian Technologies Limited is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 11:00 am. Room Mission II.
Wednesday, January 9 at 11:00 am. Room Mission II.
Circadian an emerging leader in the field of angiogenesis-based treatments for cancer. Focusing on a class of drug targets called Vascular Endothelial Growth Factors (VEGFs), it seeks to develop truly novel therapies to extend and improve the lives of cancer sufferers.
Visit: http://www.circadian.com.au
Biotech Showcase™ 2013
Clearside Biomedical, Inc.
Country: United States
Country: United States
Clearside Biomedical is an ophthalmic company developing and eventually commercializing targeted therapeutics for the treatment of sight threatening diseases using a propriet...
Share this:
Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 3:30 pm. Room Hearst.
Wednesday, January 9 at 3:30 pm. Room Hearst.
Clearside Biomedical is an ophthalmic company developing and eventually commercializing targeted therapeutics for the treatment of sight threatening diseases using a proprietary, disruptive technology.
Visit: http://www.clearsidebio.com
Biotech Showcase™ 2013
Codagenix, Inc,
Country: United States
Country: United States
Codagenix Inc. utilizes a platform technology termed SAVE to construct live-attenuated viral vaccines against multiple targets. The SAVE platform "re-designs" the target virus...
Share this:
Codagenix, Inc,
Codagenix, Inc, is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 2:15 pm. Room Mission I.
Tuesday, January 8 at 2:15 pm. Room Mission I.
Codagenix Inc. utilizes a platform technology termed SAVE to construct live-attenuated viral vaccines against multiple targets. The SAVE platform "re-designs" the target virus's entire genome yielding a vaccine strain. Proteins of SAVE-designed vaccine strain are one hundred percent identical to the virulent strain. Targets include – Influenza A virus, Dengue, RSV.
Visit: http://codagenix.com
Biotech Showcase™ 2013
Cognition Therapeutics
Country: United States
Country: United States
Cognition Therapeutics, Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associate...
Share this:
Cognition Therapeutics
Cognition Therapeutics is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 3:15 pm. Room Mission II.
Wednesday, January 9 at 3:15 pm. Room Mission II.
Cognition Therapeutics, Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain.
Visit: http://www.cogrx.com
Biotech Showcase™ 2013
Cognoptix
Country: United States
Country: United States
Cognoptix is developing a non-invasive eye test to aid in the diagnosis of Alzheimer's disease. Its goal is to provide a quick, predictive, reliable, cost-effective and widely...
Share this:
Cognoptix
Cognoptix is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 2:45 pm. Room Mission I.
Monday, January 7 at 2:45 pm. Room Mission I.
Cognoptix is developing a non-invasive eye test to aid in the diagnosis of Alzheimer's disease. Its goal is to provide a quick, predictive, reliable, cost-effective and widely available test enabling early diagnosis and treatment of Alzheimer’s disease, thereby significantly improving the standard of care for Alzheimer’s patients.
Visit: http://www.cognoptix.com
Biotech Showcase™ 2013
CollabRx, Inc
(NASDAQ:CLRX)
Country: United States
(NASDAQ:CLRX)
Country: United States
CollabRx is a data analytics company that uses cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world’s knowledge on mo...
Share this:
CollabRx, Inc
CollabRx, Inc is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 2:45 pm. Room Powell.
Wednesday, January 9 at 2:45 pm. Room Powell.
CollabRx is a data analytics company that uses cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world’s knowledge on molecular medicine with specific insights from the nation’s top clinical experts.
Visit: http://www.collabrx.com
Biotech Showcase™ 2013
Complexa, Inc
Country: United States
Country: United States
Complexa is focused on discovering and developing innovative therapies for the treatment inflammatory and metabolic diseases with an initial focus on acute and chronic kidney...
Share this:
Complexa, Inc
Complexa, Inc is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 3:15 pm. Room Hearst.
Monday, January 7 at 3:15 pm. Room Hearst.
Complexa is focused on discovering and developing innovative therapies for the treatment inflammatory and metabolic diseases with an initial focus on acute and chronic kidney disease. Its lead compounds activate the body’s own protective mechanisms against inflammatory injury and metabolic stress.
Visit: http://complexarx.com
Biotech Showcase™ 2013
Contrafect Corporation
Country: United States
Country: United States
ContraFect is developing biotherapeutics for resistant, life threatening infections. Its lead compound, CF-301, is a bacteriophage lysin, which is an enzyme that digests bacte...
Share this:
Contrafect Corporation
Contrafect Corporation is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 9:45 am. Room Mission I.
Tuesday, January 8 at 9:45 am. Room Mission I.
Track: Track B
Country: United States
Ownership: PRIVATE
Country: United States
Ownership: PRIVATE
ContraFect is developing biotherapeutics for resistant, life threatening infections. Its lead compound, CF-301, is a bacteriophage lysin, which is an enzyme that digests bacterial cell walls, killing bacteria immediately upon contact. The initial indication is Staph bacteremia. It will begin human clinical trials in Q1 2013.
Visit: http://www.contrafect.com
Biotech Showcase™ 2013
Coyote Pharmaceuticals
Country: United States
Country: United States
Coyote is focused on treating orphan and neurodegenerative diseases through the modulation of cellular networks vital to maintaining “physiological balance,” commonly know...
Share this:
Coyote Pharmaceuticals
Coyote Pharmaceuticals is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 2:45 pm. Room Mission I.
Wednesday, January 9 at 2:45 pm. Room Mission I.
Coyote is focused on treating orphan and neurodegenerative diseases through the modulation of cellular networks vital to maintaining “physiological balance,” commonly known as homeostasis. Coyote’s lead drug candidate, CNS-102, is being developed initially to treat Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD).
Visit: http://www.coyotepharma.com
Biotech Showcase™ 2013
Cristal Delivery
Country: Netherlands
Country: Netherlands
Cristal Delivery’s technology, CriPec®, enables the development of nanomedicines with optimized drug disposition that boosts therapeutic efficacy, tolerability and commerc...
Share this:
Cristal Delivery
Cristal Delivery is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 3:45 pm. Room Hearst.
Monday, January 7 at 3:45 pm. Room Hearst.
Cristal Delivery’s technology, CriPec®, enables the development of nanomedicines with optimized drug disposition that boosts therapeutic efficacy, tolerability and commercial potential. The combination of CriPec® with drugs will change existing therapies and will open up new disease areas.
Visit: http://cristaldelivery.com
Biotech Showcase™ 2013
Cryoport, Inc.
(OTCBB:CYRX)
Country: United States
(OTCBB:CYRX)
Country: United States
CryoPort has developed a game changing solution to the challenge of shipping biological materials, such as vaccines, cell lines, and specimens, under frozen storage conditions...
Share this:
Cryoport, Inc.
Cryoport, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 9:00 am. Room Powell.
Monday, January 7 at 9:00 am. Room Powell.
CryoPort has developed a game changing solution to the challenge of shipping biological materials, such as vaccines, cell lines, and specimens, under frozen storage conditions. The turn-key shipping process maintains -150ºC temperatures for 10+ days and is a 'green' game changing alternative to current dry ice shipping methods.
Visit: http://www.cryoport.com
Biotech Showcase™ 2013
Crystal Bioscience
Country: United States
Country: United States
Crystal Bioscience isolates affinity-matured, biologically-active mAbs from immunized chickens using its GEM technology. Our technology provides access to the avian repertoir...
Share this:
Crystal Bioscience
Crystal Bioscience is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 11:00 am. Room Mission I.
Monday, January 7 at 11:00 am. Room Mission I.
Crystal Bioscience isolates affinity-matured, biologically-active mAbs from immunized chickens using its GEM technology. Our technology provides access to the avian repertoire which, by virtue of the phylogenetic distance between chickens and humans, contains mAbs that are unique.
Biotech Showcase™ 2013
CureVac GmbH
Country: Germany
Country: Germany
CureVac is developing an entirely novel class of therapies based on a fundamental new understanding of the medical potential of messenger RNA (mRNA). CureVac aims to use this ...
Share this:
CureVac GmbH
CureVac GmbH is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 2:15 pm. Room Hearst.
Wednesday, January 9 at 2:15 pm. Room Hearst.
CureVac is developing an entirely novel class of therapies based on a fundamental new understanding of the medical potential of messenger RNA (mRNA). CureVac aims to use this new class of therapeutic mRNA vaccines and adjuvants to transform the treatment of oncological diseases and the prophylaxis for infectious diseases.
Visit: http://www.curevac.de
Biotech Showcase™ 2013
Cyclacel Pharmaceuticals, Inc
(NASDAQ:CYCC)
Country: United States
(NASDAQ:CYCC)
Country: United States
Cyclacel is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and othe...
Share this:
Cyclacel Pharmaceuticals, Inc
Cyclacel Pharmaceuticals, Inc is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 3:15 pm. Room Powell.
Monday, January 7 at 3:15 pm. Room Powell.
Cyclacel is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates.
Visit: http://cyclacel.com
Biotech Showcase™ 2013
CytoDyn
(PINK:CYDY)
Country: United States
(PINK:CYDY)
Country: United States
CytoDyn Inc's principal activity is to develop a monoclonal antibody for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection and Feline Immunodeficien...
Share this:
CytoDyn
CytoDyn is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 3:15 pm. Room Powell.
Wednesday, January 9 at 3:15 pm. Room Powell.
CytoDyn Inc's principal activity is to develop a monoclonal antibody for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection and Feline Immunodeficiency Virus (FIV) infection. CytoDyn anticipates initiating Phase IIB clinical trials in 2013.
Visit: http://www.cytodyn.com
Biotech Showcase™ 2013
CytomX Therapeutics, Inc
Country: United States
Country: United States
CytomX 's proprietary Probody™ Platform offers a highly differentiated approach to developing antibody therapeutics. Probodies are masked antibodies that remain inert in he...
Share this:
CytomX Therapeutics, Inc
CytomX Therapeutics, Inc is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 3:00 pm. Room Mission I.
Monday, January 7 at 3:00 pm. Room Mission I.
CytomX 's proprietary Probody™ Platform offers a highly differentiated approach to developing antibody therapeutics. Probodies are masked antibodies that remain inert in healthy tissue but are activated within the disease microenvironment. This technology disrupts conventional thinking about therapeutic antibody targeting. CytomX is building a diversified pipeline in oncology and inflammatory disease.
Visit: http://cytomx.com
Biotech Showcase™ 2013
Cytori Therapeutics, Inc.
(NASDAQ:CYTX)
Country: United States
(NASDAQ:CYTX)
Country: United States
Cytori is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and to repair soft tissue defects. Scientif...
Share this:
Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 11:30 am. Room Powell.
Tuesday, January 8 at 11:30 am. Room Powell.
Cytori is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and to repair soft tissue defects. Scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. Cytori believes these cells can be applied across multiple “ischemic” conditions.
Visit: http://www.cytori.com
Biotech Showcase™ 2013
CytRx Corporation
(NASDAQ:CYTR)
Country: United States
(NASDAQ:CYTR)
Country: United States
CytRx specializes in oncology with two programs in clinical development. CytRx recently had a positive meeting with the FDA on the Phase 3 clinical trial design for aldoxorub...
Share this:
CytRx Corporation
CytRx Corporation is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 2:15 pm. Room Mission II.
Tuesday, January 8 at 2:15 pm. Room Mission II.
CytRx specializes in oncology with two programs in clinical development. CytRx recently had a positive meeting with the FDA on the Phase 3 clinical trial design for aldoxorubicin for treating 2nd-line soft tissue sarcomas. The company is well capitalized and will have results from four clinical trials in 2013.
Visit: http://cytrx.com
Biotech Showcase™ 2013
DCPrime
Country: Netherlands
Country: Netherlands
DCPrime is a clinical stage vaccine company dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) platform DCOne™. This platform has the abili...
Share this:
DCPrime
DCPrime is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 9:15 am. Room Mission I.
Tuesday, January 8 at 9:15 am. Room Mission I.
DCPrime is a clinical stage vaccine company dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) platform DCOne™. This platform has the ability to generate off-the-shelf DC-based vaccines with endogenously expressed cancer antigens. DCPrime is the only company with an allogeneic antigen presenting cell (APC) cancer therapy.
Visit: http://www.dcprime.nl/
Biotech Showcase™ 2013
DeBioPharm
Country: Switzerland
Country: Switzerland
Debiopharm Group™ (Debiopharm) is a group of companies focused on the development of innovative prescription drugs targeting unmet medical needs. Debiopharm independently fu...
Share this:
DeBioPharm
DeBioPharm is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 3:30 pm. Room Mission I.
Tuesday, January 8 at 3:30 pm. Room Mission I.
Debiopharm Group™ (Debiopharm) is a group of companies focused on the development of innovative prescription drugs targeting unmet medical needs. Debiopharm independently funds the global development of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, as well as regulatory affairs.
Visit: http://www.debiopharm.com
Biotech Showcase™ 2013
DelMar Pharmaceuticals
Country: Canada
Country: Canada
Del Mar was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. Its ...
Share this:
DelMar Pharmaceuticals
DelMar Pharmaceuticals is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 10:00 am. Room Mission II.
Wednesday, January 9 at 10:00 am. Room Mission II.
Del Mar was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. Its lead asset is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme.
Visit: http://www.delmarpharma.com
Biotech Showcase™ 2013
Denovo Biomarkers
Country: United States
Country: United States
Denovo’s biomarker discovery platform technology, is useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy or side effect, can identif...
Share this:
Denovo Biomarkers
Denovo Biomarkers is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 2:15 pm. Room Hearst.
Monday, January 7 at 2:15 pm. Room Hearst.
Denovo’s biomarker discovery platform technology, is useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy or side effect, can identify biomarkers correlated to patients' responsiveness to drug candidates retrospectively, enabling biopharmaceutical companies to design new trials in targeted patient populations.
Visit: http://denovobiomarkers.com
Biotech Showcase™ 2013
Diagnoplex SA
Country: Switzerland
Country: Switzerland
Diagnoplex’s lead product, Colox®, is a convenient and minimally-invasive blood test developed for the systematic screening of colorectal cancer. The gene signature underly...
Share this:
Diagnoplex SA
Diagnoplex SA is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 10:30 am. Room Mission I.
Monday, January 7 at 10:30 am. Room Mission I.
Diagnoplex’s lead product, Colox®, is a convenient and minimally-invasive blood test developed for the systematic screening of colorectal cancer. The gene signature underlying Colox® has been designed to detect early and advanced disease stages with outstanding results and reliability.
Visit: http://www.diagnoplex.com
Biotech Showcase™ 2013
DioGenix
Country: United States
Country: United States
DioGenix is a molecular diagnostics company developing a series of novel tests that target immune-mediated neurological conditions. Its lead program is focused on developing a...
Share this:
DioGenix
DioGenix is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 2:00 pm. Room Mission I.
Tuesday, January 8 at 2:00 pm. Room Mission I.
DioGenix is a molecular diagnostics company developing a series of novel tests that target immune-mediated neurological conditions. Its lead program is focused on developing a highly accurate panel of tests to detect early disease events, predict progression, and guide choice of therapy in Multiple Sclerosis and other immune-mediated neurological conditions.
Visit: http://diogenix.com
Biotech Showcase™ 2013
DiscGenics
Country: United States
Country: United States
DiscGenics is a spinal therapeutics company developing proprietary adult human disc stem cells with a tissue engineering approach to treat patients debilitated by degenerative...
Share this:
DiscGenics
DiscGenics is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 11:15 am. Room Mission I.
Tuesday, January 8 at 11:15 am. Room Mission I.
DiscGenics is a spinal therapeutics company developing proprietary adult human disc stem cells with a tissue engineering approach to treat patients debilitated by degenerative disc disease (DDD).
Visit: http://www.discgenics.com
Biotech Showcase™ 2013
DLVR Therapeutics Inc.
Country: Canada
Country: Canada
DLVR is developing a novel, HDL-mimicking nanoparticle delivery system for cancer. DLVR’s nontoxic and biodegradable particle co-opts the native targeting of HDL to SR-B1 ...
Share this:
DLVR Therapeutics Inc.
DLVR Therapeutics Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 3:30 pm. Room Mission I.
Monday, January 7 at 3:30 pm. Room Mission I.
DLVR is developing a novel, HDL-mimicking nanoparticle delivery system for cancer. DLVR’s nontoxic and biodegradable particle co-opts the native targeting of HDL to SR-B1 which is overexpressed in many cancers, and enables active targeting and delivery of RNAi to the cytosol of cancer cells bypassing known cellular pathways leading to RNAi degradation.
Visit: http://dlvrtherapeutics.ca/
Biotech Showcase™ 2013
Domainex Ltd
Country: United Kingdom
Country: United Kingdom
Domainex, a drug discovery company, reduces industry average drug discovery timelines by as much as 30% through its novel proprietary technologies and a highly focused and int...
Share this:
Domainex Ltd
Domainex Ltd is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 4:00 pm. Room Mission I.
Monday, January 7 at 4:00 pm. Room Mission I.
Domainex, a drug discovery company, reduces industry average drug discovery timelines by as much as 30% through its novel proprietary technologies and a highly focused and integrated approach to medicinal chemistry and computational chemistry. These technologies and Domainex’s approach enable it to tackle a greater range of drug target classes.
Visit: http://domainex.co.uk
Biotech Showcase™ 2013
Druggability Technologies Holdings Ltd
Country: United States
Country: United States
Druggability is developing and commercializing its proprietary NanoActive™ high throughput technology platform, delivering significant improvements in compound solubility, p...
Share this:
Druggability Technologies Holdings Ltd
Druggability Technologies Holdings Ltd is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 9:30 am. Room Mission I.
Tuesday, January 8 at 9:30 am. Room Mission I.
Druggability is developing and commercializing its proprietary NanoActive™ high throughput technology platform, delivering significant improvements in compound solubility, permeability and pharmacokinetics that can be applied across a diverse universe of chemical and biological compounds.
Visit: http://drgtco.com/
Biotech Showcase™ 2013
Dynamis Pharmaceuticals inc
Country: United States
Country: United States
Dynamis is dedicated to developing small molecule drugs for complications of diabetes, and also chronic inflammatory conditions. Its scientists have identified a unique targe...
Share this:
Dynamis Pharmaceuticals inc
Dynamis Pharmaceuticals inc is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 4:15 pm. Room Mission II.
Tuesday, January 8 at 4:15 pm. Room Mission II.
Dynamis is dedicated to developing small molecule drugs for complications of diabetes, and also chronic inflammatory conditions. Its scientists have identified a unique target for drug intervention to prevent and/or treat chronic inflammatory diseases such as diabetic complications, scleroderma, arthritis, and chronic wounds.
Biotech Showcase™ 2013
Echo Therapeutics, Inc.
(NASDAQ:ECTE)
Country: United States
(NASDAQ:ECTE)
Country: United States
Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system. Its target is patients who could benefit from gluco...
Share this:
Echo Therapeutics, Inc.
Echo Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 2:45 pm. Room Powell.
Monday, January 7 at 2:45 pm. Room Powell.
Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system. Its target is patients who could benefit from glucose monitoring in the hospital setting, including critical care.
Visit: http://echotx.com
Biotech Showcase™ 2013
Elk OrthoBiologics
Country: Australia
Country: Australia
Elk is developing therapies for the treatment aseptic loosening of prosthetic implants such as artificial hips. The new treatment is based upon gene directed enzyme-prodrug t...
Share this:
Elk OrthoBiologics
Elk OrthoBiologics is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 4:45 pm. Room Mission I.
Tuesday, January 8 at 4:45 pm. Room Mission I.
Elk is developing therapies for the treatment aseptic loosening of prosthetic implants such as artificial hips. The new treatment is based upon gene directed enzyme-prodrug therapy (‘GDEPT’), a modern strategy that eliminates a target tissue without the need for highly invasive surgery.
Visit: http://www.broadvector.com
Biotech Showcase™ 2013
Embera NeuroTherapeutics, Inc
Country: United States
Country: United States
Embera is developing a novel drug combination (EMB-001) to address significant unmet needs in the $3.5B smoking cessation market where the medical costs of smoking related dis...
Share this:
Embera NeuroTherapeutics, Inc
Embera NeuroTherapeutics, Inc is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 9:30 am. Room Hearst.
Tuesday, January 8 at 9:30 am. Room Hearst.
Embera is developing a novel drug combination (EMB-001) to address significant unmet needs in the $3.5B smoking cessation market where the medical costs of smoking related diseases exceed $96B annually. Animal studies demonstrated EMB-001 to be significantly more effective than the clinical market leader Chantix®, Pfizer’s $732M smoking cessation product.
Visit: http://emberaneuro.com
Biotech Showcase™ 2013
ENDECE Neural, LLC
Country: United States
Country: United States
ENDECE Neural has discovered and is developing NDC-1308, potentially the first drug to directly induce remyelination of demyelinated axons. Unlike current MS drugs, NDC-1308 ...
Share this:
ENDECE Neural, LLC
ENDECE Neural, LLC is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 2:45 pm. Room Hearst.
Tuesday, January 8 at 2:45 pm. Room Hearst.
ENDECE Neural has discovered and is developing NDC-1308, potentially the first drug to directly induce remyelination of demyelinated axons. Unlike current MS drugs, NDC-1308 may reverse progression and restore muscle control, mobility and cognition to patients.
Visit: http://endece.com
Biotech Showcase™ 2013
EPIOMED Therapeutics, Inc
Country: United States
Country: United States
Epiomed is a semi-virtual pharmaceutical organization engaged in the discovery and development of novel central nervous system (CNS) drugs, with a primary focus on anti-emetic...
Share this:
EPIOMED Therapeutics, Inc
EPIOMED Therapeutics, Inc is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 3:30 pm. Room Mission II.
Wednesday, January 9 at 3:30 pm. Room Mission II.
Epiomed is a semi-virtual pharmaceutical organization engaged in the discovery and development of novel central nervous system (CNS) drugs, with a primary focus on anti-emetics (anti-vomiting and anti-nausea), anxiolytics and performance sustainment agents.
Biotech Showcase™ 2013
ERBA Diagnostics
(NYSEAMEX:ERB)
Country: United States
(NYSEAMEX:ERB)
Country: United States
ERBA DIAGNOSTICS is an emerging company in the global Healthcare domain operating in the core business segment of In Vitro Diagnostics (IVD).
Share this:
ERBA Diagnostics
ERBA Diagnostics is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 9:00 am. Room Powell.
Tuesday, January 8 at 9:00 am. Room Powell.
ERBA DIAGNOSTICS is an emerging company in the global Healthcare domain operating in the core business segment of In Vitro Diagnostics (IVD).
Visit: http://www.erbamannheim.com/
Biotech Showcase™ 2013
Esperion Therapeutics
Country: United States
Country: United States
Esperion, with an experienced management team and investors, is focused on therapies to prevent, treat, and reverse cardiovascular and metabolic diseases. Esperion was the fi...
Share this:
Esperion Therapeutics
Esperion Therapeutics is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 9:15 am. Room Hearst.
Monday, January 7 at 9:15 am. Room Hearst.
Esperion, with an experienced management team and investors, is focused on therapies to prevent, treat, and reverse cardiovascular and metabolic diseases. Esperion was the first to demonstrate that atherosclerosis could be rapidly reversed by enhancing removal of cholesterol from the arteries through HDL therapy.
Visit: http://www.esperion.com
Biotech Showcase™ 2013
Etubics Corporation
Country: United States
Country: United States
Etubics is a clinical stage company, which has developed a proprietary immunization platform technology. The Etubics Platform consists of a method to deliver immunizing agents...
Share this:
Etubics Corporation
Etubics Corporation is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 9:30 am. Room Mission I.
Wednesday, January 9 at 9:30 am. Room Mission I.
Etubics is a clinical stage company, which has developed a proprietary immunization platform technology. The Etubics Platform consists of a method to deliver immunizing agents or antigens to induce both arms of the immune system—cell mediated immunity (CMI) and antibodies.
Visit: http://etubics.com
Biotech Showcase™ 2013
Evestra, Inc.
Country: United States
Country: United States
Evestra is dedicated to the development of innovative and differentiated women's healthcare products which target fertility control, HRT, and major gynecological unmet medical...
Share this:
Evestra, Inc.
Evestra, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 3:15 pm. Room Hearst.
Tuesday, January 8 at 3:15 pm. Room Hearst.
Evestra is dedicated to the development of innovative and differentiated women's healthcare products which target fertility control, HRT, and major gynecological unmet medical need indications. The Company has generated a number of product leads based on innovative drug delivery technology and new chemical entities.
Visit: http://evestra.com
Biotech Showcase™ 2013
Ezose Sciences Inc.
Country: United States
Country: United States
Ezose Sciences is dedicated to advancing glycomics to enable new innovations in disease diagnosis and therapy. Its proprietary GlycanMap® technology platform introduces a new...
Share this:
Ezose Sciences Inc.
Ezose Sciences Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 11:30 am. Room Mission I.
Monday, January 7 at 11:30 am. Room Mission I.
Ezose Sciences is dedicated to advancing glycomics to enable new innovations in disease diagnosis and therapy. Its proprietary GlycanMap® technology platform introduces a new dimension to biomarker discovery by enabling glycomics research on a scale comparable to genomics and proteomics.
Visit: http://www.ezose.com
Biotech Showcase™ 2013
Fluorinov Pharma
Country: Canada
Country: Canada
Fluorinov’s unique fluorine-based medicinal chemistry creates best-in-class medicines and a rich pipeline of New Chemical Entities (NCEs). Two potentially best-in-class, ora...
Share this:
Fluorinov Pharma
Fluorinov Pharma is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 5:00 pm. Room Mission II.
Tuesday, January 8 at 5:00 pm. Room Mission II.
Track: Track C
Country: Canada
Ownership: PRIVATE
Country: Canada
Ownership: PRIVATE
Fluorinov’s unique fluorine-based medicinal chemistry creates best-in-class medicines and a rich pipeline of New Chemical Entities (NCEs). Two potentially best-in-class, orally available, small molecule programs are entering IND-enabling studies in the substantial markets for multiple myeloma, rheumatoid arthritis and pain/epilepsy.
Biotech Showcase™ 2013
FluoroPharma
(OTCBB:FPMI)
Country: United States
(OTCBB:FPMI)
Country: United States
FluoroPharma engages in the discovery, development and commercialization of proprietary medical diagnostic imaging products. The company’s initial focus is the development o...
Share this:
FluoroPharma
FluoroPharma is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 11:00 am. Room Powell.
Monday, January 7 at 11:00 am. Room Powell.
FluoroPharma engages in the discovery, development and commercialization of proprietary medical diagnostic imaging products. The company’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD).
Visit: http://www.fluoropharma.com
Biotech Showcase™ 2013
FPRT Bio
Country: United States
Country: United States
FPRT Bio was formed to develop XPro1595, a disease modifying drug for the treatment of neurodegenerative diseases including ALS, Parkinson's disease and Alzheimer's disease. ...
Share this:
FPRT Bio
FPRT Bio is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 4:45 pm. Room Hearst.
Tuesday, January 8 at 4:45 pm. Room Hearst.
FPRT Bio was formed to develop XPro1595, a disease modifying drug for the treatment of neurodegenerative diseases including ALS, Parkinson's disease and Alzheimer's disease. Phase I studies will begin after completion of this $10M Series A financing. They expect an exit via M&A after completion of Phase II POC.
Visit: http://fprtbio.com
Biotech Showcase™ 2013
Galactica Pharmaceuticals, Inc.
Galactica Pharmaceuticals is an "IND-ready" biopharmaceutical company focused exclusively on the development of a RAGE (Receptor for Advanced Glycation End Products) fusion pr...
Share this:
Galactica Pharmaceuticals, Inc.
Galactica Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2013
Wedneday, January 9 at 10:15 am. Room Hearst.
Wedneday, January 9 at 10:15 am. Room Hearst.
Track: Track A
Ownership: PRIVATE
Ownership: PRIVATE
Galactica Pharmaceuticals is an "IND-ready" biopharmaceutical company focused exclusively on the development of a RAGE (Receptor for Advanced Glycation End Products) fusion protein, initially for the treatment of diabetes and diabetic complications. In addition, our molecule may be effective in the treatment of both the dry and wet forms of age-related macular degeneration, autoimmune/inflammatory disorders and possibly Alzheimer's disease. In 8-and 44-week preclinical studies conducted with Galactica's RAGE protein by Dr. Timothy S. Kern of Case Western Reserve University, Galactica's molecule was shown to be the first molecule of any type to have demonstrated in vivo efficacy against at least two major diabetic complications, which is of enormous clinical significance. Galactica has a clear path to its first IND filing in 15 months.
Biotech Showcase™ 2013
GC-Rise Pharmaceutical Co.Ltd
Country: China
Country: China
GC-Rise is focused on women’s healthcare in anti-aging, reproductive health, gynecologic oncology and autoimmune diseases, dermatology and beauty health, central nervous sys...
Share this:
GC-Rise Pharmaceutical Co.Ltd
GC-Rise Pharmaceutical Co.Ltd is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 3:45 pm. Room Mission I.
Tuesday, January 8 at 3:45 pm. Room Mission I.
GC-Rise is focused on women’s healthcare in anti-aging, reproductive health, gynecologic oncology and autoimmune diseases, dermatology and beauty health, central nervous system disorders. It intends to become a leading pharmaceutical enterprises in China.
Visit: http://www.gc-rise.com
Biotech Showcase™ 2013
Genalyte
Country: United States
Country: United States
Genalyte, a tools company, provides the ability to perform many biological tests on a single sample, a capability termed multiplexing. Using a proprietary mass-manufacturable ...
Share this:
Genalyte
Genalyte is scheduled to present at Biotech Showcase™ 2013
Wedneday, January 9 at 9:45 am. Room Mission I.
Wedneday, January 9 at 9:45 am. Room Mission I.
Genalyte, a tools company, provides the ability to perform many biological tests on a single sample, a capability termed multiplexing. Using a proprietary mass-manufacturable silicon chip, its platform can perform 10s-100s of tests on a few microliters of sample in about 10 minutes for a cost of a few dollars.
Visit: http://www.genalyte.com
Biotech Showcase™ 2013
Gencia
Country: United States
Country: United States
Gencia is a discovery company dedicated to the development of mitochondrial therapeutics. It has developed large and small molecule drug candidates targeting orphan and large...
Share this:
Gencia
Gencia is scheduled to present at Biotech Showcase™ 2013
Wedneday, January 9 at 11:00 am. Room Hearst.
Wedneday, January 9 at 11:00 am. Room Hearst.
Gencia is a discovery company dedicated to the development of mitochondrial therapeutics. It has developed large and small molecule drug candidates targeting orphan and large market indications including orphan mitochondrial disorders, Alzheimer’s, Parkinson’s, Huntington’s disease and others. Its lead clinical candidate is currently scheduled for IND filing during 2013.
Visit: http://www.genciabiotech.com
Biotech Showcase™ 2013
Genervon Biopharmaceuticals
Country: United States
Country: United States
Genervon discovered MNTF, a novel patented family of 9 human master regulators of the nervous system highly expressed during week 9 of embryonic development. These Master Reg...
Share this:
Genervon Biopharmaceuticals
Genervon Biopharmaceuticals is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 10:45 am. Room Hearst.
Tuesday, January 8 at 10:45 am. Room Hearst.
Genervon discovered MNTF, a novel patented family of 9 human master regulators of the nervous system highly expressed during week 9 of embryonic development. These Master Regulators are potent disease modification drug candidates modulating many pathways including inflammation, apoptosis, hypoxia etc. MNTF/GM600 is in Phase II CNS clinical trials.
Visit: http://genervon.com
Biotech Showcase™ 2013
GeNeuro SA
Country: Switzerland
Country: Switzerland
GeNeuro is pioneering a new understanding on the role of human endogenous retrovirus (HERVs) in the onset and development of poorly understood diseases such as Multiple Sclero...
Share this:
GeNeuro SA
GeNeuro SA is scheduled to present at Biotech Showcase™ 2013
Wedneday, January 9 at 10:45 am. Room Mission I.
Wedneday, January 9 at 10:45 am. Room Mission I.
GeNeuro is pioneering a new understanding on the role of human endogenous retrovirus (HERVs) in the onset and development of poorly understood diseases such as Multiple Sclerosis (MS) and certain subtypes of schizophrenia. Its lead product GNbAC1 is a mAb against HERV-W, which plays a key role in MS.
Visit: http://www.geneuro.com
Biotech Showcase™ 2013
GENFIT
(EPA:ALGFT)
Country: France
(EPA:ALGFT)
Country: France
GENFIT is focused on the diagnosis and treatment of diabetes related complications, including liver and cardiovascular diseases. GENFIT's most advanced drug candidate, curre...
Share this:
GENFIT
GENFIT is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 10:30 am. Room Mission II.
Monday, January 7 at 10:30 am. Room Mission II.
GENFIT is focused on the diagnosis and treatment of diabetes related complications, including liver and cardiovascular diseases. GENFIT's most advanced drug candidate, currently in phase IIb, is well positioned to become a first-in-class therapy for NASH. GENFIT seeks Investors and pharma partners to fund late-stage clinical development of GFT505.
Visit: http://genfit.com
Biotech Showcase™ 2013
Genmab
(CPH:GEN)
Country: United States
(CPH:GEN)
Country: United States
Genmab specializes in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Genmab’s validated and next generation antibody...
Share this:
Genmab
Genmab is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 2:45 pm. Room Mission II.
Monday, January 7 at 2:45 pm. Room Mission II.
Genmab specializes in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Genmab’s validated and next generation antibody technologies are expected to provide a steady stream of future product candidates.
Visit: http://genmab.com
Biotech Showcase™ 2013
GICARE PHARMA Inc
Country: Canada
Country: Canada
Gicare, a specialty pharma company, specializes in the development of analgesic drugs for pain management for patients undegoing sedation-free colonoscopy. Such analgesic dru...
Share this:
GICARE PHARMA Inc
GICARE PHARMA Inc is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 11:30 am. Room Hearst.
Tuesday, January 8 at 11:30 am. Room Hearst.
Gicare, a specialty pharma company, specializes in the development of analgesic drugs for pain management for patients undegoing sedation-free colonoscopy. Such analgesic drugs are non-centrally-acting opioid agonists which has affinity to kappa and mu receptors. The lead candidate, GIC-1001, is currently in Phase I.
Visit: http://gicarepharma.com
Biotech Showcase™ 2013
Good Start Genetics, Inc.
Country: United States
Country: United States
Good Start Genetics® is a leading molecular diagnostics company that benefits doctors and patients by setting the new gold standard for routine genetic carrier screening for ...
Share this:
Good Start Genetics, Inc.
Good Start Genetics, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 9:45 am. Room Mission I.
Monday, January 7 at 9:45 am. Room Mission I.
Good Start Genetics® is a leading molecular diagnostics company that benefits doctors and patients by setting the new gold standard for routine genetic carrier screening for inherited diseases.
Visit: http://www.gsgenetics.com
Biotech Showcase™ 2013
Harbour Antibodies
Country: Netherlands
Country: Netherlands
Harbour Antibodies commercialises transgenic mouse antibody platforms, creating fully human H2L2 antibodies and HCAbs. There is extensive IP protection, with FTO in US, Europe...
Share this:
Harbour Antibodies
Harbour Antibodies is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 3:00 pm. Room Hearst.
Wednesday, January 9 at 3:00 pm. Room Hearst.
Harbour Antibodies commercialises transgenic mouse antibody platforms, creating fully human H2L2 antibodies and HCAbs. There is extensive IP protection, with FTO in US, Europe and other markets. A strategic pharma alliance validated the technology. Harbour is now expanding operations, financed by broad industry licensing and other forms of capital investment.
Visit: http://harbourantibodies.com
Biotech Showcase™ 2013
Hatchtech Pty Ltd
Country: Australia
Country: Australia
Hatchtech is a venture-funded, specialty pharmaceutical company developing a proprietary next generation head lice treatment, DeOvo™, which has successfully completed a Phas...
Share this:
Hatchtech Pty Ltd
Hatchtech Pty Ltd is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 4:30 pm. Room Hearst.
Wednesday, January 9 at 4:30 pm. Room Hearst.
Hatchtech is a venture-funded, specialty pharmaceutical company developing a proprietary next generation head lice treatment, DeOvo™, which has successfully completed a Phase 2b clinical trial and is poised to enter Phase 3. Subject to regulatory approval, market launch is anticipated in 2015.
Visit: http://www.hatchtech.com.au
Biotech Showcase™ 2013
Histogenics Corporation
Country: United States
Country: United States
Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair a...
Share this:
Histogenics Corporation
Histogenics Corporation is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 11:45 am. Room Mission I.
Tuesday, January 8 at 11:45 am. Room Mission I.
Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. The company’s flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility.
Visit: http://www.histogenics.com
Biotech Showcase™ 2013
IgDraSol
Country: United States
Country: United States
IGDRASOL is a developer of personalized nanoparticle paclitaxel. IG-001 will be undergoing phase III clinical development in the US and Igdrasol is actively recruiting invest...
Share this:
IgDraSol
IgDraSol is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 5:00 pm. Room Hearst.
Monday, January 7 at 5:00 pm. Room Hearst.
IGDRASOL is a developer of personalized nanoparticle paclitaxel. IG-001 will be undergoing phase III clinical development in the US and Igdrasol is actively recruiting investigators for these trials. IG-001/Genexol-PM is approved in Korea and marketed by Samyang Biopharmaceuticals.
Visit: http://www.igdrasol.com/
Biotech Showcase™ 2013
IGNYTA, Inc.
Country: United States
Country: United States
Ignyta is providing next generation products and services for personalized medicine in autoimmune diseases. It is transforming the quality of biomarkers and tests available to...
Share this:
IGNYTA, Inc.
IGNYTA, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 4:30 pm. Room Mission I.
Monday, January 7 at 4:30 pm. Room Mission I.
Ignyta is providing next generation products and services for personalized medicine in autoimmune diseases. It is transforming the quality of biomarkers and tests available to rheumatologists and patients to help them make more indiv
Visit: http://nexdx.com
Biotech Showcase™ 2013
ImmuneWorks
Country: United States
Country: United States
ImmuneWorks biologic candidate is ready to advance into Phase 2 clinical trials in idiopathic pulmonary fibrosis. The therapeutic indications for ImmuneWorks' asset may be ex...
Share this:
ImmuneWorks
ImmuneWorks is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 3:30 pm. Room Hearst.
Tuesday, January 8 at 3:30 pm. Room Hearst.
ImmuneWorks biologic candidate is ready to advance into Phase 2 clinical trials in idiopathic pulmonary fibrosis. The therapeutic indications for ImmuneWorks' asset may be extendable to other fibrotic lung diseases including lung transplant rejection, severe/chronic asthma and COPD.
Visit: http://immuneworks.com
Biotech Showcase™ 2013
ImmunoCellular Therapeutics
(NYSEAMEX:IMUC)
Country: United States
(NYSEAMEX:IMUC)
Country: United States
ImmunoCellular is a clinical-stage company developing immune-based therapies for the treatment of cancer. It focuses on immunotherapies that target cancer stem cells in additi...
Share this:
ImmunoCellular Therapeutics
ImmunoCellular Therapeutics is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 10:30 am. Room Mission II.
Wednesday, January 9 at 10:30 am. Room Mission II.
ImmunoCellular is a clinical-stage company developing immune-based therapies for the treatment of cancer. It focuses on immunotherapies that target cancer stem cells in addition to normal cancer cells. Its lead product, a dendritic cell based therapeutic cancer vaccine, is in a Phase 2b clinical trial for newly diagnosed glioblastoma multiforme.
Visit: http://www.imuc.com
Biotech Showcase™ 2013
Immunocore
Country: United Kingdom
Country: United Kingdom
Immunocore has the world’s only engineered T cell receptor platform, capable of targeting any cancer antigen, including intracellular. The company has one programme in the c...
Share this:
Immunocore
Immunocore is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 10:15 am. Room Mission I.
Monday, January 7 at 10:15 am. Room Mission I.
Immunocore has the world’s only engineered T cell receptor platform, capable of targeting any cancer antigen, including intracellular. The company has one programme in the clinic and a long pipeline of TCRs targeting validated targets and intends to secure partnerships in 2013 and beyond.
Visit: http://immunocore.com
Biotech Showcase™ 2013
ImmunoGenetix Therapeutics, Inc.
Country: United States
Country: United States
ImmunoGenetix is developing advanced DNA immunotherapies for HIV infection. Its lead product candidate, GenePro™, is a DNA therapeutic vaccine incorporating a proprietary D...
Share this:
ImmunoGenetix Therapeutics, Inc.
ImmunoGenetix Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 10:45 am. Room Hearst.
Wednesday, January 9 at 10:45 am. Room Hearst.
ImmunoGenetix is developing advanced DNA immunotherapies for HIV infection. Its lead product candidate, GenePro™, is a DNA therapeutic vaccine incorporating a proprietary DNA composition that yields high levels of gene expression and non-infectious HIV protein production, inducing a robust antibody and a long term memory t cell immune response similar to elite controllers.
Visit: http://www.igxbio.com
Biotech Showcase™ 2013
Immunome Inc.
Country: United States
Country: United States
Immunome's Acceleroma, a closed-loop product engine, simultaneously discovers new disease targets and therapeutics for patients/diseases that express those targets. It is fo...
Share this:
Immunome Inc.
Immunome Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 10:45 am. Room Mission I.
Monday, January 7 at 10:45 am. Room Mission I.
Immunome's Acceleroma, a closed-loop product engine, simultaneously discovers new disease targets and therapeutics for patients/diseases that express those targets. It is focused on oncology where it is developing best in class antibody drug conjugates for the treatment for various adenocarcinomas.
Visit: http://immunomeinc.com
Biotech Showcase™ 2013
Immunophotonics, Inc.
Country: United States
Country: United States
Immunophotonics is a search-oriented company in the frontline of cancer vaccine research. Its objective is to develop and introduce Laser-Assisted Immunotherapy, which is an i...
Share this:
Immunophotonics, Inc.
Immunophotonics, Inc. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 2:00 pm. Room Hearst.
Wednesday, January 9 at 2:00 pm. Room Hearst.
Immunophotonics is a search-oriented company in the frontline of cancer vaccine research. Its objective is to develop and introduce Laser-Assisted Immunotherapy, which is an in situ cancer vaccine (inCVAX), one of the most innovative and promising modalities for metastatic tumors to have emerged in the cancer research world.
Visit: http://immunophotonics.com/
Biotech Showcase™ 2013
Immunovaccine, Inc.
(TSE:IMV)
Country: Canada
(TSE:IMV)
Country: Canada
Immunovaccine Inc. applies its novel adjuvanting platform, DepoVaxTM, to the development of vaccines. Its platform technology is a formulation that provides controlled and pr...
Share this:
Immunovaccine, Inc.
Immunovaccine, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 3:45 pm. Room Mission II.
Monday, January 7 at 3:45 pm. Room Mission II.
Immunovaccine Inc. applies its novel adjuvanting platform, DepoVaxTM, to the development of vaccines. Its platform technology is a formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. The DepoVax platform is a combination of antigens, immune enhancers formulated in liposomes, and then in oil.
Visit: http://www.imvaccine.com
Biotech Showcase™ 2013
Indel Therapeutics Inc.
Country: Canada
Country: Canada
Indel Therapeutics is focused on developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiot...
Share this:
Indel Therapeutics Inc.
Indel Therapeutics Inc. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 2:30 pm. Room Mission I.
Wednesday, January 9 at 2:30 pm. Room Mission I.
Indel Therapeutics is focused on developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery pro
Visit: http://www.indelrx.com
Biotech Showcase™ 2013
Inflammatory Response Research
Country: United States
Country: United States
Inflammatory Response Research develops products for the treatment of inflammatory disorders and conditions. Its initial product in the development stage, is a combination of ...
Share this:
Inflammatory Response Research
Inflammatory Response Research is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 4:30 pm. Room Mission I.
Tuesday, January 8 at 4:30 pm. Room Mission I.
Track: Track B
Country: United States
Ownership: PRIVATE
Country: United States
Ownership: PRIVATE
Inflammatory Response Research develops products for the treatment of inflammatory disorders and conditions. Its initial product in the development stage, is a combination of levocetirizine and montelukast for treatment of influenza, the common cold and chronic sinusitis.
Biotech Showcase™ 2013
Inhibikase Therapeutics, Inc.
Country: United States
Country: United States
Inhibikase, a revenue generating company, has created the first small molecules capable of treating bacterial or viral infections through a common mechanism of action without ...
Share this:
Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 3:00 pm. Room Hearst.
Monday, January 7 at 3:00 pm. Room Hearst.
Inhibikase, a revenue generating company, has created the first small molecules capable of treating bacterial or viral infections through a common mechanism of action without stimulating resistance. Its first products will prevent progressive multifocal leukoencephalopathy, a fatal brain infection, and treat hepatitis C.
Visit: http://www.inhibikase.com
Biotech Showcase™ 2013
Innovent Biologics, Inc.
Country: China
Country: China
Innovent Biologics is dedicated to the development and manufacturing of monoclonal antibodies to be marketed in China and elsewhere around the world. Funded by the venture ar...
Share this:
Innovent Biologics, Inc.
Innovent Biologics, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 1:45 pm. Room Mission I.
Monday, January 7 at 1:45 pm. Room Mission I.
Innovent Biologics is dedicated to the development and manufacturing of monoclonal antibodies to be marketed in China and elsewhere around the world. Funded by the venture arm of Fidelity, Lilly Ventures, and Suzhou bioBay. Innovent is actively seeking product candidates for in-licensing and co-development.
Visit: http://www.innoventbio.com
Biotech Showcase™ 2013
Inovio Pharmaceuticals, Inc.
(NYSEAMEX:INO)
Country: United States
(NYSEAMEX:INO)
Country: United States
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-stra...
Share this:
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 10:30 am. Room Mission II.
Tuesday, January 8 at 10:30 am. Room Mission II.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza.
Visit: http://www.inovio.com
Biotech Showcase™ 2013
Intensity Therapeutics, Inc.
Country: United States
Country: United States
Intensity Therapeutics is developing novel formulations of existing cytotoxic drugs for intratumoral injection to achieve high cellular uptake. In vivo data generated has sho...
Share this:
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 1:45 pm. Room Hearst.
Monday, January 7 at 1:45 pm. Room Hearst.
Intensity Therapeutics is developing novel formulations of existing cytotoxic drugs for intratumoral injection to achieve high cellular uptake. In vivo data generated has shown more effective tumor shrinkage with significantly less toxicity over the same drug given systemically (e.g. IV).
Biotech Showcase™ 2013
International Stem Cell Corporation
(PINK:ISCO)
Country: United States
(PINK:ISCO)
Country: United States
ISCO is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) to treat diseases of the brain, liver and eye. ISCO scientists have created the fir...
Share this:
International Stem Cell Corporation
International Stem Cell Corporation is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 9:30 am. Room Mission II.
Monday, January 7 at 9:30 am. Room Mission II.
ISCO is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) to treat diseases of the brain, liver and eye. ISCO scientists have created the first parthenogenic stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation.
Biotech Showcase™ 2013
Invion Limited
(ASX:IVX)
Country: Australia
(ASX:IVX)
Country: Australia
Invion is a clinical-stage company that targets chronic inflammation. It has two phase II proprietary therapeutic candidates: INV102 – a repurposed inverse beta agonist; and...
Share this:
Invion Limited
Invion Limited is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 9:00 am. Room Mission II.
Wednesday, January 9 at 9:00 am. Room Mission II.
Invion is a clinical-stage company that targets chronic inflammation. It has two phase II proprietary therapeutic candidates: INV102 – a repurposed inverse beta agonist; and Cpn10 – a modified natural immunomodulator, in three phase II clinical programs: asthma, smoking cessation (chronic bronchitis) and lupus.
Visit: http://www.invion.com.au
Biotech Showcase™ 2013
InVivo Therapeutics
(OTCBB:NVIV)
Country: United States
(OTCBB:NVIV)
Country: United States
InVivo is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. Founded in 2005 b...
Share this:
InVivo Therapeutics
InVivo Therapeutics is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 10:30 am. Room Powell.
Wednesday, January 9 at 10:30 am. Room Powell.
InVivo is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. Founded in 2005 based on proprietary technology co-invented by Robert S.Langer.
Biotech Showcase™ 2013
Juventas Therapeutics, Inc.
Country: United States
Country: United States
Juventas is developing a pipeline of regenerative therapies. Its lead product, JVS-100 encodes Stromal cell-Derived Factor-1 (SDF-1) which has been shown to protect and repair...
Share this:
Juventas Therapeutics, Inc.
Juventas Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 10:30 am. Room Mission I.
Tuesday, January 8 at 10:30 am. Room Mission I.
Juventas is developing a pipeline of regenerative therapies. Its lead product, JVS-100 encodes Stromal cell-Derived Factor-1 (SDF-1) which has been shown to protect and repair tissue following organ damage. It is currently enrolling Phase II clinical trials for JVS-100 in patients with heart failure and critical limb ischemia (CLI).
Visit: http://www.juventasinc.com
Biotech Showcase™ 2013
Karus Therapeutics Ltd
Country: United Kingdom
Country: United Kingdom
Karus, which recently closed a Series B financing round with leading investors, is a leader in the development of innovative medicines with breakthrough potential in treating ...
Share this:
Karus Therapeutics Ltd
Karus Therapeutics Ltd is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 11:15 am. Room Mission I.
Monday, January 7 at 11:15 am. Room Mission I.
Karus, which recently closed a Series B financing round with leading investors, is a leader in the development of innovative medicines with breakthrough potential in treating inflammation and cancer. The Company’s scientific excellence is reflected in its proprietary PI3K and HDAC6 inhibitor programs.
Visit: http://karustherapeutics.com
Biotech Showcase™ 2013
KemPharm, Inc.
Country: United States
Country: United States
KemPharm, focused on safer therapies for ADHD, pain and cardiovascular disease, uses its patent-applied technology to improve existing drugs and shorten the development timel...
Share this:
KemPharm, Inc.
KemPharm, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 4:00 pm. Room Hearst.
Monday, January 7 at 4:00 pm. Room Hearst.
KemPharm, focused on safer therapies for ADHD, pain and cardiovascular disease, uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.
Visit: http://kempharm.com
Biotech Showcase™ 2013
KineMed, Inc.
Country: United States
Country: United States
KineMed is at the cutting edge of personalized medicine and biomarkers. Its technology combines specific diagnostic information with targeted drugs, employing advanced biomark...
Share this:
KineMed, Inc.
KineMed, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 2:00 pm. Room Mission I.
Monday, January 7 at 2:00 pm. Room Mission I.
KineMed is at the cutting edge of personalized medicine and biomarkers. Its technology combines specific diagnostic information with targeted drugs, employing advanced biomarker technology, secured by over 80 patents, and validated by various projects and concomitant revenues from dozens of pharma, biotech, and foundation companies.
Visit: http://kinemed.com
Biotech Showcase™ 2013
KLOX Technologies Inc.
Country: Canada
Country: Canada
KLOX Technologies is focused on the development and commercialization of a unique, non-invasive technology using a multiple LED lighting system that interacts with an oxygen-r...
Share this:
KLOX Technologies Inc.
KLOX Technologies Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 9:00 am. Room Hearst.
Tuesday, January 8 at 9:00 am. Room Hearst.
KLOX Technologies is focused on the development and commercialization of a unique, non-invasive technology using a multiple LED lighting system that interacts with an oxygen-rich gel containing light-trapping molecules. KLOX’s cosmetics and medical devices are destined for the rapidly growing aesthetics, dental, dermatological and tissue repair markets.
Biotech Showcase™ 2013
Kymab Ltd
Country: United Kingdom
Country: United Kingdom
Kymab is using a proprietary transgenic antibody platform, Kymouse, to discover and develop fully human monoclonal antibody drugs. The technology used to design the Kymouse st...
Share this:
Kymab Ltd
Kymab Ltd is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 4:00 pm. Room Mission I.
Wednesday, January 9 at 4:00 pm. Room Mission I.
Kymab is using a proprietary transgenic antibody platform, Kymouse, to discover and develop fully human monoclonal antibody drugs. The technology used to design the Kymouse strains originated from the Wellcome Trust Sanger Institute in Cambridge, UK.
Visit: http://www.kymab.com
Biotech Showcase™ 2013
Lipocine Inc.
Country: United States
Country: United States
Lipocine, a specialty pharma company focused on drug delivery, has a Phase III ready oral testosterone; the first oral for preterm birth and all-bioidentical oral combination...
Share this:
Lipocine Inc.
Lipocine Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 9:45 am. Room Hearst.
Tuesday, January 8 at 9:45 am. Room Hearst.
Lipocine, a specialty pharma company focused on drug delivery, has a Phase III ready oral testosterone; the first oral for preterm birth and all-bioidentical oral combination contraceptive in clinical development; and, it will file three NDAs for cough/cold combination products within the next 12 months.
Visit: http://www.lipocine.com
Biotech Showcase™ 2013
Livtech Inc.
Country: Japan
Country: Japan
LivTech translates cutting-edge cancer stem cell research in Japan into the discovery and development of therapeutic antibodies targeting malignant tumors. It has developed a ...
Share this:
Livtech Inc.
Livtech Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 4:15 pm. Room Hearst.
Tuesday, January 8 at 4:15 pm. Room Hearst.
LivTech translates cutting-edge cancer stem cell research in Japan into the discovery and development of therapeutic antibodies targeting malignant tumors. It has developed a unique research platform that targets carcinogenesis and has a pipeline of lead candidates with significant anti-cancer activity.
Visit: http://www.livtech.co.jp
Biotech Showcase™ 2013
Longevity Biotech, Inc
Country: United States
Country: United States
Longevity is a preclinical company positioned to capitalize on a groundbreaking new class of therapeutics, Hybridtides®. The Hybridtide® platform technology stabilizes biolo...
Share this:
Longevity Biotech, Inc
Longevity Biotech, Inc is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 4:00 pm. Room Mission I.
Tuesday, January 8 at 4:00 pm. Room Mission I.
Longevity is a preclinical company positioned to capitalize on a groundbreaking new class of therapeutics, Hybridtides®. The Hybridtide® platform technology stabilizes biologic targets both digestively and structurally. The Hybridtide® product profile results in metabolically stable and highly active biotherapeutics. Longevity is developing Hybridtides® metabolic, cardiovascular and oncology disease.
Biotech Showcase™ 2013
MabVax Therapeutics, Inc.
Country: United States
Country: United States
MabVax is a clinical stage biotechnology company focused on the discovery and development of vaccine and antibody based therapies to address unmet medical needs in the treatme...
Share this:
MabVax Therapeutics, Inc.
MabVax Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 3:45 pm. Room Mission I.
Monday, January 7 at 3:45 pm. Room Mission I.
MabVax is a clinical stage biotechnology company focused on the discovery and development of vaccine and antibody based therapies to address unmet medical needs in the treatment of cancer. It has two vaccine programs in Phase 2 clinical trials and a fully human antibody therapeutic candidate ready for GMP manufacturing.
Visit: http://www.mabvax.com
Biotech Showcase™ 2013
Marsala Biotech Inc.
Country: Canada
Country: Canada
Marsala is developing Endostatin gene therapy (E10A) for the treatment of various solid tumors like Head and Neck Cancer. A Phase-II clinical trial with positive results was ...
Share this:
Marsala Biotech Inc.
Marsala Biotech Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 5:00 pm. Room Mission I.
Tuesday, January 8 at 5:00 pm. Room Mission I.
Marsala is developing Endostatin gene therapy (E10A) for the treatment of various solid tumors like Head and Neck Cancer. A Phase-II clinical trial with positive results was completed in Head and Neck Cancer patients. Phase II/ III clinical trials of E10A are planned for 2013 in North America.
Biotech Showcase™ 2013
Matinas BioPharma, Inc.
Country: United States
Country: United States
Matinas focuses on developing MAT9001, an omega-3-based therapeutic for cardiovascular indications. MAT9001 targets hypertriglyceridemia and mixed dyslipidemia, therapeutic a...
Share this:
Matinas BioPharma, Inc.
Matinas BioPharma, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 9:30 am. Room Hearst.
Monday, January 7 at 9:30 am. Room Hearst.
Track: Track A
Country: United States
Ownership: PRIVATE
Country: United States
Ownership: PRIVATE
Matinas focuses on developing MAT9001, an omega-3-based therapeutic for cardiovascular indications. MAT9001 targets hypertriglyceridemia and mixed dyslipidemia, therapeutic areas comprising 30-40MM patients in the US alone. MAT9001 differentiates from other omega-3-products through superior potency and differentiating clinical features. Its management team launched Lovaza while at Reliant Pharmaceuticals.
Visit: http://matinasbiopharma.com/
Biotech Showcase™ 2013
MaxCyte, Inc.
Country: United States
Country: United States
MaxCyte is a leader in cell transfection, bringing to market its patented flow electroporation technology. MaxCyte is focused in applying its significant capabilities in the d...
Share this:
MaxCyte, Inc.
MaxCyte, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 10:00 am. Room Mission I.
Tuesday, January 8 at 10:00 am. Room Mission I.
MaxCyte is a leader in cell transfection, bringing to market its patented flow electroporation technology. MaxCyte is focused in applying its significant capabilities in the discovery, development, and manufacturing of virtually all classes of innovative therapeutics targeting a broad range of chronic and acute diseases.
Visit: http://www.maxcyte.com
Biotech Showcase™ 2013
MBio Diagnostics, Inc.
Country: United States
Country: United States
Mbio, a developer of testing systems for rapid diagnosis of multiple diseases, was selected by the Foundation for Innovative New Diagnostics, to provide its immunoassay system...
Share this:
MBio Diagnostics, Inc.
MBio Diagnostics, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 2:30 pm. Room Hearst.
Monday, January 7 at 2:30 pm. Room Hearst.
Mbio, a developer of testing systems for rapid diagnosis of multiple diseases, was selected by the Foundation for Innovative New Diagnostics, to provide its immunoassay system for a point-of-care tuberculosis screening study in Peru and Vietnam.
Visit: http://www.mbiodx.com
Biotech Showcase™ 2013
MDXHEALTH SA
(EBR:MDXH)
Country: Belgium
(EBR:MDXH)
Country: Belgium
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. Its f...
Share this:
MDXHEALTH SA
MDXHEALTH SA is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 11:30 am. Room Powell.
Monday, January 7 at 11:30 am. Room Powell.
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. Its first commercial product, the ConfirmMDxTM for Prostate Cancer test, has been shown to help distinguish patients who have a true-negative biopsy from those who may have occult cancer.
Visit: http://www.mdxhealth.com
Biotech Showcase™ 2013
Medbox Inc.
Country: United States
Country: United States
MedBox is a producer of dispensing systems that allow pharmacies, assisted living facilities, prisons, hospitals, doctors’ offices, and alternative medicine clinics to help ...
Share this:
Medbox Inc.
Medbox Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 4:45 pm. Room Mission II.
Tuesday, January 8 at 4:45 pm. Room Mission II.
MedBox is a producer of dispensing systems that allow pharmacies, assisted living facilities, prisons, hospitals, doctors’ offices, and alternative medicine clinics to help manage employee possession of sensitive drugs. Medbox and its patented device and software for dispensing medical marijuana with strong security, electronic inventory management and compliance safeguards.
Biotech Showcase™ 2013
Medistem, Inc
(OTCBB:MEDS)
Country: United States
(OTCBB:MEDS)
Country: United States
Medistem, Inc., is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stim...
Share this:
Medistem, Inc
Medistem, Inc is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 4:15 pm. Room Powell.
Wednesday, January 9 at 4:15 pm. Room Powell.
Medistem, Inc., is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue.
Visit: http://www.medisteminc.com
Biotech Showcase™ 2013
Melanovus Oncology
Country: United States
Country: United States
Melanovus is a late pre-clinical company that has discovered and is developing innovative new therapies and diagnostics for late stage melanoma. Its portfolio includes five c...
Share this:
Melanovus Oncology
Melanovus Oncology is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 10:45 am. Room Mission I.
Tuesday, January 8 at 10:45 am. Room Mission I.
Melanovus is a late pre-clinical company that has discovered and is developing innovative new therapies and diagnostics for late stage melanoma. Its portfolio includes five compounds with demonstrated pre-clinical activity in various stages of melanoma. These first-in-class compounds are known as Multi-Target Inhibitors™ (MTIs).
Visit: http://www.melanovus.com
Biotech Showcase™ 2013
Merus B.V.
Country: Netherlands
Country: Netherlands
Merus discovers and develops innovative therapeutic human multispecific antibodies with improved clinical efficacy based on its common light chain (cLC) antibody technologies....
Share this:
Merus B.V.
Merus B.V. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 11:15 am. Room Hearst.
Wednesday, January 9 at 11:15 am. Room Hearst.
Merus discovers and develops innovative therapeutic human multispecific antibodies with improved clinical efficacy based on its common light chain (cLC) antibody technologies. It has a pipeline of bispecific antibodies for improved cancer therapy and is about to commence GMP manufacturing for two IND enabling studies.
Visit: http://www.merus.nl
Biotech Showcase™ 2013
MetaStat Inc.
(OTCBB:MTST)
Country: United States
(OTCBB:MTST)
Country: United States
MetaStat intends to help clinicians better "customize" treatment, by positively identifying patients who need aggressive therapy and by sparing those at low risk from the side...
Share this:
MetaStat Inc.
MetaStat Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 3:45 pm. Room Powell.
Monday, January 7 at 3:45 pm. Room Powell.
MetaStat intends to help clinicians better "customize" treatment, by positively identifying patients who need aggressive therapy and by sparing those at low risk from the side effects and expense of chemotherapy and radiation.
Visit: http://www.metastat.com/
Biotech Showcase™ 2013
Microbiotix, Inc.
Country: United States
Country: United States
Microbiotix, a small molecule, anti-infective company, has four novel compound series in research and development. It has an active research program to discover a broad-spectr...
Share this:
Microbiotix, Inc.
Microbiotix, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 4:45 pm. Room Hearst.
Monday, January 7 at 4:45 pm. Room Hearst.
Microbiotix, a small molecule, anti-infective company, has four novel compound series in research and development. It has an active research program to discover a broad-spectrum antibiotic that targets DNA replication of drug-resistant Gram-positive and Gram-negative bacteria.
Visit: http://www.microbiotix.com
Biotech Showcase™ 2013
MiniVax
Country: United States
Country: United States
MiniVax is focused on the development of novel solutions for the treatment and prevention of opportunistic infections.
Share this:
MiniVax
MiniVax is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 2:15 pm. Room Mission I.
Wednesday, January 9 at 2:15 pm. Room Mission I.
MiniVax is focused on the development of novel solutions for the treatment and prevention of opportunistic infections.
Visit: http://www.minivaxcorp.com/
Biotech Showcase™ 2013
Mnemosyne Pharmaceuticals
Country: United States
Country: United States
Mnemosyne is a drug discovery company developing subunit specific NMDA receptor modulators to address learning and memory disorders associated with neuropsychiatric diseases i...
Share this:
Mnemosyne Pharmaceuticals
Mnemosyne Pharmaceuticals is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 1:45 pm. Room Mission I.
Wednesday, January 9 at 1:45 pm. Room Mission I.
Mnemosyne is a drug discovery company developing subunit specific NMDA receptor modulators to address learning and memory disorders associated with neuropsychiatric diseases including schizophrenia, traumatic brain injury, and ADHD.
Biotech Showcase™ 2013
MRI Interventions, Inc.
(OTCBB:MRIC)
Country: United States
(OTCBB:MRIC)
Country: United States
MRI is a leader in the field of real-time MRI-guided interventions. It is a commercial stage medical device company focused on creating innovative platforms for performing th...
Share this:
MRI Interventions, Inc.
MRI Interventions, Inc. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 3:45 pm. Room Powell.
Wednesday, January 9 at 3:45 pm. Room Powell.
MRI is a leader in the field of real-time MRI-guided interventions. It is a commercial stage medical device company focused on creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart.
Visit: http://mriinterventions.com
Biotech Showcase™ 2013
MSDx
Country: United States
Country: United States
MSDx is a personalized medicine company for brain diseases. MSDx blood tests offer critical data to improve treatment decisions helping slow disease progression for the patien...
Share this:
MSDx
MSDx is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 3:15 pm. Room Hearst.
Wednesday, January 9 at 3:15 pm. Room Hearst.
MSDx is a personalized medicine company for brain diseases. MSDx blood tests offer critical data to improve treatment decisions helping slow disease progression for the patient while reducing lifelong healthcare costs.
Visit: http://msdx.co
Biotech Showcase™ 2013
MSI Methylation Sciences Inc.
Country: Canada
Country: Canada
Methylation Sciences (“MSI”) is developing pharmaceuticals which are proven to be clinically effective but which have not been exploited in major pharmaceutical markets. ...
Share this:
MSI Methylation Sciences Inc.
MSI Methylation Sciences Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 4:30 pm. Room Hearst.
Monday, January 7 at 4:30 pm. Room Hearst.
Methylation Sciences (“MSI”) is developing pharmaceuticals which are proven to be clinically effective but which have not been exploited in major pharmaceutical markets. The first molecule, s-adenosyl methionine (SAMe), has a large body of human evidence demonstrating effectiveness as a treatment for depression, including Major Depressive Disorder or “MDD”.
Biotech Showcase™ 2013
NanoViricides, Incorporated
(OTCBB:NNVC)
Country: United States
(OTCBB:NNVC)
Country: United States
NanoViricides, a development stage company, is developing its novel nanoviricide™ class of drug candidates designed to specifically attack enveloped virus particles and to d...
Share this:
NanoViricides, Incorporated
NanoViricides, Incorporated is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 3:15 pm. Room Mission II.
Monday, January 7 at 3:15 pm. Room Mission II.
NanoViricides, a development stage company, is developing its novel nanoviricide™ class of drug candidates designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, among others.
Biotech Showcase™ 2013
Navidea Biopharmaceuticals
(NYSEAMEX:NAVB)
Country: United States
(NYSEAMEX:NAVB)
Country: United States
Navidea Biopharmaceuticals is focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four age...
Share this:
Navidea Biopharmaceuticals
Navidea Biopharmaceuticals is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 10:00 am. Room Powell.
Monday, January 7 at 10:00 am. Room Powell.
Navidea Biopharmaceuticals is focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four agents to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care.
Visit: http://www.navidea.com
Biotech Showcase™ 2013
Neuralstem, Inc.
(NYSEAMEX:CUR)
Country: United States
(NYSEAMEX:CUR)
Country: United States
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities and to control the differentiatio...
Share this:
Neuralstem, Inc.
Neuralstem, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 3:45 pm. Room Powell.
Tuesday, January 8 at 3:45 pm. Room Powell.
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities and to control the differentiation of these cells. Neuralstem completed the final surgery of an FDA-approved Phase I NSI-566 clinical trial for ALS, which has orphan drug designation.
Visit: http://neuralstem.com
Biotech Showcase™ 2013
NewGen Therapeutics
Country: United States
Country: United States
Share this:
NewGen Therapeutics
NewGen Therapeutics is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 4:15 pm. Room Hearst.
Monday, January 7 at 4:15 pm. Room Hearst.
Track: Track A
Country: United States
Ownership: PRIVATE
Country: United States
Ownership: PRIVATE
No information entered
Visit: http://newgenther.com
Biotech Showcase™ 2013
NovaBay Pharmaceuticals Inc.
(NYSEAMEX:NBY)
Country: United States
(NYSEAMEX:NBY)
Country: United States
NovaBay Pharmaceuticals, Inc. is a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of infections due to bacteri...
Share this:
NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 2:45 pm. Room Mission II.
Tuesday, January 8 at 2:45 pm. Room Mission II.
NovaBay Pharmaceuticals, Inc. is a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of infections due to bacteria, fungi and virus, including antibiotic-resistant infections.
Visit: http://www.novabaypharma.com
Biotech Showcase™ 2013
Numab AG
Country: Switzerland
Country: Switzerland
Numab innovates and develops antibody-based therapeutics with a particular focus on the discovery of protein therapeutics against non-traditional antibody targets, such as com...
Share this:
Numab AG
Numab AG is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 10:30 am. Room Mission I.
Wednesday, January 9 at 10:30 am. Room Mission I.
Numab innovates and develops antibody-based therapeutics with a particular focus on the discovery of protein therapeutics against non-traditional antibody targets, such as complex membrane proteins. Its proprietary discovery technology is well suited to approach this class of drug-targets that formerly was inaccessible to most protein-binder platforms.
Visit: http://www.numab.com
Biotech Showcase™ 2013
Numera
Country: United States
Country: United States
Numera provides healthcare companies and consumers with affordable telehealth solutions for care management and general wellness programs. The company’s platform-independent...
Share this:
Numera
Numera is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 9:30 am. Room Mission I.
Monday, January 7 at 9:30 am. Room Mission I.
Numera provides healthcare companies and consumers with affordable telehealth solutions for care management and general wellness programs. The company’s platform-independent approach offers the most options to capture, analyze and transmit objective health measurement data and integrate it with virtually any electronic health record.
Visit: http://numera.com
Biotech Showcase™ 2013
NuPotential
Country: United States
Country: United States
NuPotential is developing next generation therapies for type 2 diabetes, obesity and cancer. Its NP-Reprog cell reprogramming platform is the basis for its issued foundation ...
Share this:
NuPotential
NuPotential is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 4:30 pm. Room Mission II.
Wednesday, January 9 at 4:30 pm. Room Mission II.
NuPotential is developing next generation therapies for type 2 diabetes, obesity and cancer. Its NP-Reprog cell reprogramming platform is the basis for its issued foundation patent demonstrating that small molecule inhibition of epigenetic factors involved in single carbon metabolism can reprogram somatic cells to a pluripotent state.
Visit: http://nupotential.com
Biotech Showcase™ 2013
OgenX Therapeutics
Country: United States
Country: United States
Ogenx, a development-stage company, focused on advancing its Redoxagen Platform of small molecule mitochondrial medicines for the treatment of debilitating diseases. It has t...
Share this:
OgenX Therapeutics
OgenX Therapeutics is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 4:15 pm. Room Mission II.
Wednesday, January 9 at 4:15 pm. Room Mission II.
Ogenx, a development-stage company, focused on advancing its Redoxagen Platform of small molecule mitochondrial medicines for the treatment of debilitating diseases. It has two lead programs for veterinary use for Canine Lymphosarcoma and Canine Mast Cell Tumors; and a lead clinical-stage program in humans with for Dry Age-Related Macular Degeneration.
Visit: http://www.ogenx.com/
Biotech Showcase™ 2013
Ohr Pharmaceutical Inc
(OTCBB:OHRP)
Country: United States
(OTCBB:OHRP)
Country: United States
Ohr is focused on two lead compounds currently being investigated in clinical phase II trials: Squalamine Eye Drops for the treatment of the wet form of age-related macular de...
Share this:
Ohr Pharmaceutical Inc
Ohr Pharmaceutical Inc is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 2:15 pm. Room Mission II.
Monday, January 7 at 2:15 pm. Room Mission II.
Ohr is focused on two lead compounds currently being investigated in clinical phase II trials: Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia.
Visit: http://ohrpharmaceutical.com
Biotech Showcase™ 2013
OncBioMune
Country: United States
Country: United States
Oncbiomune, specializing in innovative cancer treatment, has proprietary rights to a breast cancer vaccine and prostate cancer vaccine, as well as a process for the growth of ...
Share this:
OncBioMune
OncBioMune is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 4:00 pm. Room Hearst.
Wednesday, January 9 at 4:00 pm. Room Hearst.
Oncbiomune, specializing in innovative cancer treatment, has proprietary rights to a breast cancer vaccine and prostate cancer vaccine, as well as a process for the growth of cancer tumor cells. Its principals have the knowledge of an untapped market for the treatment of cancer with antisense.
Visit: http://www.oncbiomune.com
Biotech Showcase™ 2013
Oncolix, Inc.
Country: United States
Country: United States
Oncolix is a clinical-stage company developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian and breast cancer. The aim of Oncolix's product develop...
Share this:
Oncolix, Inc.
Oncolix, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 10:00 am. Room Hearst.
Tuesday, January 8 at 10:00 am. Room Hearst.
Oncolix is a clinical-stage company developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian and breast cancer. The aim of Oncolix's product development is to bring to market agents with increased efficacy and decreased toxicity in ovarian and breast cancer therapy through targeted therapies.
Visit: http://sbcglobal.net
Biotech Showcase™ 2013
Oncology Research International Limited
Country: Australia
Country: Australia
Oncology Research International’s technology involves the discovery and/or rational design of molecules from plants that have a unique mode of action that enables the targe...
Share this:
Oncology Research International Limited
Oncology Research International Limited is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 2:15 pm. Room Mission I.
Monday, January 7 at 2:15 pm. Room Mission I.
Track: Track B
Country: Australia
Ownership: PRIVATE
Country: Australia
Ownership: PRIVATE
Oncology Research International’s technology involves the discovery and/or rational design of molecules from plants that have a unique mode of action that enables the targeting of cancer cells in preference to normal cells. ORIL's compounds enter the cancer cell membrane and inhibit receptors to send the signals to the cancer cell nucleus.
Visit: http://www.oril.com.au/
Biotech Showcase™ 2013
OncoPlex Diagnostics
Country: United States
Country: United States
OncoPlex is developing leading-edge, proprietary diagnostics that enable physicians to choose appropriate targeted therapies for their patients. It focuses on measuring the ...
Share this:
OncoPlex Diagnostics
OncoPlex Diagnostics is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 3:45 pm. Room Mission II.
Wednesday, January 9 at 3:45 pm. Room Mission II.
OncoPlex is developing leading-edge, proprietary diagnostics that enable physicians to choose appropriate targeted therapies for their patients. It focuses on measuring the functional proteins that make a patient’s tumor unique. It plans to deliver a clear, reliable report on every case, typically within five days.
Visit: http://www.oncoplexdx.com
Biotech Showcase™ 2013
Oncos Therapeutics
Country: Finland
Country: Finland
Oncos develops next generaion oncolytic vaccines. Its lead agent, CGTG-102, optimized based on clinical data with 10 novel vaccine candidates in 300 cancer patients, is comple...
Share this:
Oncos Therapeutics
Oncos Therapeutics is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 4:30 pm. Room Hearst.
Tuesday, January 8 at 4:30 pm. Room Hearst.
Oncos develops next generaion oncolytic vaccines. Its lead agent, CGTG-102, optimized based on clinical data with 10 novel vaccine candidates in 300 cancer patients, is completing a phase I trial in EU and beginning a phase I in the USA, and has a clear registration strategy in Soft Tissue Sarcoma..
Visit: http://www.oncos.com
Biotech Showcase™ 2013
OncoSec Medical
(PINK:ONCS)
Country: United States
(PINK:ONCS)
Country: United States
OncoSec is developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. It currently has three Phase II clinical trial...
Share this:
OncoSec Medical
OncoSec Medical is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 3:45 pm. Room Mission II.
Tuesday, January 8 at 3:45 pm. Room Mission II.
OncoSec is developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. It currently has three Phase II clinical trials with a focus on melanoma, Merkel cell lymphoma, and cutaneous T-cell lymphoma. OncoSec Medicals's core technology is based upon its proprietary use of an electroporation platform.
Visit: http://www.oncosec.com
Biotech Showcase™ 2013
Opsona Therapeutics Ltd.
Country: Ireland
Country: Ireland
Opsona is focused on novel therapeutic approaches to key targets of the innate immune system. Its lead product, a fully human monoclonal IgG4 antibody targeting Toll-like-rece...
Share this:
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 11:45 am. Room Hearst.
Tuesday, January 8 at 11:45 am. Room Hearst.
Opsona is focused on novel therapeutic approaches to key targets of the innate immune system. Its lead product, a fully human monoclonal IgG4 antibody targeting Toll-like-receptor-2 has demonstrated activity in a number of animal models and recently was tested successfully in a phase 1 clinical trial in healthy volunteers.
Visit: http://www.opsona.com
Biotech Showcase™ 2013
Opthea Pty Ltd
Country: Australia
Country: Australia
Opthea is developing biologic inhibitors of VEGF-C as therapeutics for ophthalmological diseases. It has exclusive rights to develop VEGF-C inhibitors for eye diseases and cur...
Share this:
Opthea Pty Ltd
Opthea Pty Ltd is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 9:45 am. Room Hearst.
Wednesday, January 9 at 9:45 am. Room Hearst.
Opthea is developing biologic inhibitors of VEGF-C as therapeutics for ophthalmological diseases. It has exclusive rights to develop VEGF-C inhibitors for eye diseases and currently has two therapeutics in its pipeline: VGX-100, a human antibody that selectively blocks VEGF-C; and, VGX-300, a soluble receptor that blocks both VEGF-C and VEGF-D.
Visit: http://www.opthea.com
Biotech Showcase™ 2013
Organovo
(PINK:ONVO)
Country: United States
(PINK:ONVO)
Country: United States
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The company is working in collaboration with pharma...
Share this:
Organovo
Organovo is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 1:45 pm. Room Powell.
Tuesday, January 8 at 1:45 pm. Room Powell.
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The company is working in collaboration with pharmaceutical and academic partners to develop human biological disease models in three dimensions that enable therapeutic drug discovery and development.
Visit: http://www.organovo.com
Biotech Showcase™ 2013
ORYZON GENOMICS, S.A.
Country: Spain
Country: Spain
Oryzon has a unique drug discovery platform in epigenetic targets with a special emphasis in Histone Lysine Demethylases. It is a leader in LSD1/KDM1, a target for leukemias ...
Share this:
ORYZON GENOMICS, S.A.
ORYZON GENOMICS, S.A. is scheduled to present at Biotech Showcase™ 2013
Monday , January 7 at 11:45 A.M.. Room Hearst.
Monday , January 7 at 11:45 A.M.. Room Hearst.
Oryzon has a unique drug discovery platform in epigenetic targets with a special emphasis in Histone Lysine Demethylases. It is a leader in LSD1/KDM1, a target for leukemias and solid tumors, and has two preclinical programs with different LSD1i preclinical candidates.
Biotech Showcase™ 2013
Pacific Edge Limited
(NZX:PEB)
Country: New Zealand
(NZX:PEB)
Country: New Zealand
Pacific Edge is a cancer diagnostic company specializing in the discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring ...
Share this:
Pacific Edge Limited
Pacific Edge Limited is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 11:30 am. Room Mission II.
Wednesday, January 9 at 11:30 am. Room Mission II.
Pacific Edge is a cancer diagnostic company specializing in the discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. Its initial products are focused on colorectal and bladder cancer and melanoma.
Biotech Showcase™ 2013
PeriphaGen
Country: United States
Country: United States
PeriphaGen is clinical stage company focused on the development of disruptive technology as first in class neuronal gene delivery products for difficult to treat neurologic di...
Share this:
PeriphaGen
PeriphaGen is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 5:00 pm. Room Mission I.
Monday, January 7 at 5:00 pm. Room Mission I.
PeriphaGen is clinical stage company focused on the development of disruptive technology as first in class neuronal gene delivery products for difficult to treat neurologic disorders with significant unmet medical need. Its first target indications are neuropathic pain, neuropathy, and neuronal regeneration.
Visit: http://periphagen.com
Biotech Showcase™ 2013
PharmaCell BV
Country: Netherlands
Country: Netherlands
PharmaCell is a leading CMO exclusively focused in the area of cell therapy and regenerative medicine. It has experience in supporting Phase I through Phase III clinical trial...
Share this:
PharmaCell BV
PharmaCell BV is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 11:00 am. Room Mission I.
Tuesday, January 8 at 11:00 am. Room Mission I.
PharmaCell is a leading CMO exclusively focused in the area of cell therapy and regenerative medicine. It has experience in supporting Phase I through Phase III clinical trials in cell therapy in terms of manufacturing, QC, storage, in-outgoing logistics and product release through our in-house QPs.
Visit: http://www.pharmacell.nl
Biotech Showcase™ 2013
PharmaNova, Inc.
Country: United States
Country: United States
PharmaNova, applies its proprietary NovaSperse℠ & 'SMART' nanoparticle technologies to re-profile and enhance known medicines. It generates revenue by licensing and partn...
Share this:
PharmaNova, Inc.
PharmaNova, Inc. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 11:45 am. Room Mission I.
Wednesday, January 9 at 11:45 am. Room Mission I.
PharmaNova, applies its proprietary NovaSperse℠ & 'SMART' nanoparticle technologies to re-profile and enhance known medicines. It generates revenue by licensing and partnering of rights to the IP, development and commercialization of PharmaNova products and “fee for service” client-sponsored projects
Visit: http://www.pharmanovaco.com
Biotech Showcase™ 2013
PhaseRx
Country: United States
Country: United States
PhaseRx is using its proprietary SMARTT Polymer Technology to develop RNAi therapeutics against two well-validated targets in hepatocellular carcinoma (HCC), ß-catenin and ME...
Share this:
PhaseRx
PhaseRx is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 11:15 am. Room Hearst.
Monday, January 7 at 11:15 am. Room Hearst.
PhaseRx is using its proprietary SMARTT Polymer Technology to develop RNAi therapeutics against two well-validated targets in hepatocellular carcinoma (HCC), ß-catenin and MET. Both products have impressive preclinical efficacy in a preclinical model of HCC. PhaseRx will be commencing IND-enabling studies with both products in 2013.
Visit: http://www.phaserx.com/
Biotech Showcase™ 2013
PIN Pharma, Inc.
Country: United States
Country: United States
PIN Pharma is developing targeted immunotherapeutics. Its platform technology is based on Tat derivatives, which are immunostimulatory gene products that activate the immune s...
Share this:
PIN Pharma, Inc.
PIN Pharma, Inc. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 1:45 pm. Room Hearst.
Wednesday, January 9 at 1:45 pm. Room Hearst.
PIN Pharma is developing targeted immunotherapeutics. Its platform technology is based on Tat derivatives, which are immunostimulatory gene products that activate the immune system to stimulate T-cells in a controlled fashion. The lead product, PIN-2, has an outstanding safety profile and has demonstrated efficacy in advanced murine TNBC models.
Biotech Showcase™ 2013
Polynoma
Country: United States
Country: United States
Polynoma developing a therapeutic vaccine for the treatment of melanoma. It has commenced Phase 3 clinical trials for POL-103A, a polyvalent shed-antigen cancer immunotherapy...
Share this:
Polynoma
Polynoma is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 9:00 am. Room Mission I.
Monday, January 7 at 9:00 am. Room Mission I.
Polynoma developing a therapeutic vaccine for the treatment of melanoma. It has commenced Phase 3 clinical trials for POL-103A, a polyvalent shed-antigen cancer immunotherapy for the initial indication of resected stage IIB-III melanoma. Polynoma is a U.S. company within Hong Kong-based CK Life Sciences Int’l (Holdings), Inc.
Visit: http://www.polynoma.com/
Biotech Showcase™ 2013
Polyphor Ltd
Country: Switzerland
Country: Switzerland
Polyphor’s competitive edge is based on its two proprietary, innovative and complementary technology platforms, PEMfinder® and MacroFinder®. These platform technologies a...
Share this:
Polyphor Ltd
Polyphor Ltd is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 10:15 am. Room Mission I.
Wednesday, January 9 at 10:15 am. Room Mission I.
Polyphor’s competitive edge is based on its two proprietary, innovative and complementary technology platforms, PEMfinder® and MacroFinder®. These platform technologies are used in collaborative drug discovery projects with large pharma. And, Polyphor is developing and partnering its own pre-clinical and clinical portfolio of own drug candidates (PEMdrugs) in important disease areas.
Visit: http://www.polyphor.com
Biotech Showcase™ 2013
PolyTherics Ltd
Country: United Kingdom
Country: United Kingdom
PolyTherics provides site-specific conjugation technologies and novel polymers to enable the development of better biopharmaceutical products.
Share this:
PolyTherics Ltd
PolyTherics Ltd is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 4:15 pm. Room Mission I.
Wednesday, January 9 at 4:15 pm. Room Mission I.
PolyTherics provides site-specific conjugation technologies and novel polymers to enable the development of better biopharmaceutical products.
Visit: http://polytherics.com
Biotech Showcase™ 2013
Pressure BioSciences, Inc
(OTCBB:PBIO)
Country: United States
(OTCBB:PBIO)
Country: United States
Pressure Biosciences is a life sciences company focused on the development and commercialization of a novel, enabling, platform technology called pressure cycling technology (...
Share this:
Pressure BioSciences, Inc
Pressure BioSciences, Inc is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 9:30:00. Room Powell.
Wednesday, January 9 at 9:30:00. Room Powell.
Pressure Biosciences is a life sciences company focused on the development and commercialization of a novel, enabling, platform technology called pressure cycling technology ("PCT"). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions.
Biotech Showcase™ 2013
ProLynx LLC
Country: United States
Country: United States
ProLynx has developed a new format for releasable macromolecular-drug conjugates that does not require enzyme hydrolysis. The proprietary technology uses sets of novel linker...
Share this:
ProLynx LLC
ProLynx LLC is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 3:30 pm. Room Hearst.
Monday, January 7 at 3:30 pm. Room Hearst.
ProLynx has developed a new format for releasable macromolecular-drug conjugates that does not require enzyme hydrolysis. The proprietary technology uses sets of novel linkers that undergo β-elimination reactions at different, pre-programmed rates to release native drugs – peptides, proteins and small molecules – from macromolecular conjugates.
Visit: http://www.prolynxllc.com
Biotech Showcase™ 2013
ProMetic Life Sciences
(TSE:PLI)
Country: Canada
(TSE:PLI)
Country: Canada
ProMetic offers state of the art technologies for large-scale drug purification, drug development, proteomics and the elimination of pathogens. It is also developing its own n...
Share this:
ProMetic Life Sciences
ProMetic Life Sciences is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 3:15 pm. Room Mission II.
Tuesday, January 8 at 3:15 pm. Room Mission II.
ProMetic offers state of the art technologies for large-scale drug purification, drug development, proteomics and the elimination of pathogens. It is also developing its own novel therapeutics products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer, and autoimmune disease/inflammation as well as certain nephropathies.
Visit: http://prometic.com
Biotech Showcase™ 2013
Promiliad Biopharma
Country: United States
Country: United States
Promiliad utilizes unique chemistry and biology to produce highly effective compounds targeting critical needs in the pharmaceutical industry. The company currently is develop...
Share this:
Promiliad Biopharma
Promiliad Biopharma is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 11:30 am. Room Mission I.
Wednesday, January 9 at 11:30 am. Room Mission I.
Promiliad utilizes unique chemistry and biology to produce highly effective compounds targeting critical needs in the pharmaceutical industry. The company currently is developing a next-generation antibiotic effective against resistant bacterial strains such as MRSA, the market for which is estimated to be $8.5 billion annually.
Visit: http://www.promiliad.com/
Biotech Showcase™ 2013
ProQR Therapeutics BV
Country: Netherlands
Country: Netherlands
ProQR Therapeutics, founded in 2012, is focused on developing a treatment that targets the basic defect of Cystic Fibrosis. Cystic Fibrosis is an orphan disease that is curre...
Share this:
ProQR Therapeutics BV
ProQR Therapeutics BV is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 2:30 pm. Room Hearst.
Tuesday, January 8 at 2:30 pm. Room Hearst.
ProQR Therapeutics, founded in 2012, is focused on developing a treatment that targets the basic defect of Cystic Fibrosis. Cystic Fibrosis is an orphan disease that is currently untreatable and is affecting approximately 70,000 patients worldwide. Because of the lack of treatment these patients have a limited life expectancy.
Visit: http://www.proqr-tx.com
Biotech Showcase™ 2013
Prosonix Ltd
Country: United Kingdom
Country: United Kingdom
Prosonix, backed by venture investors, is focused on developing next-generation respiratory medicines delivered by metered dose inhalers and enabled by its state of the art pa...
Share this:
Prosonix Ltd
Prosonix Ltd is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 9:45 am. Room Hearst.
Monday, January 7 at 9:45 am. Room Hearst.
Prosonix, backed by venture investors, is focused on developing next-generation respiratory medicines delivered by metered dose inhalers and enabled by its state of the art particle engineering technology.
Visit: http://www.prosonix.co.uk
Biotech Showcase™ 2013
Protagonist Therapeutics
Country: United States
Country: United States
Protagonist, a venture backed company, is a peptide and peptidomimetic therapeutics company pursuing technology platform driven discovery and development of disulfide rich pep...
Share this:
Protagonist Therapeutics
Protagonist Therapeutics is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 2:00 pm. Room Hearst.
Monday, January 7 at 2:00 pm. Room Hearst.
Protagonist, a venture backed company, is a peptide and peptidomimetic therapeutics company pursuing technology platform driven discovery and development of disulfide rich peptides (DRPs).
Biotech Showcase™ 2013
PTC Therapeutics, Inc.
Country: United States
Country: United States
PTC focused on the discovery, development and commercialization of innovative small-molecule drugs. PTC applies its expertise in RNA biology and drug development to discover ...
Share this:
PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 10:00 am. Room Mission I.
Monday, January 7 at 10:00 am. Room Mission I.
PTC focused on the discovery, development and commercialization of innovative small-molecule drugs. PTC applies its expertise in RNA biology and drug development to discover novel treatments for patients living with serious and life-threatening conditions. The company’s internally discovered pipeline targets multiple therapeutic areas, including genetic disorders, oncology and infectious diseases.
Visit: http://www.ptcbio.com
Biotech Showcase™ 2013
Q Therapeutics
Country: United States
Country: United States
Q Therapeutics is developing best-in-class cell therapies that address debilitating/fatal diseases of the Central Nervous System with no known treatments. Its first product, ...
Share this:
Q Therapeutics
Q Therapeutics is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 11:00 am. Room Powell.
Tuesday, January 8 at 11:00 am. Room Powell.
Q Therapeutics is developing best-in-class cell therapies that address debilitating/fatal diseases of the Central Nervous System with no known treatments. Its first product, Q-Cells®, act as ‘mini-factories’ providing growth factors and nutritional support, removing toxins and forming the insulating myelin sheath to restore damaged and diseased neurons.
Visit: http://qthera.com
Biotech Showcase™ 2013
RaNA Therapeutics
Country: United States
Country: United States
RaNA discovers and develops highly selective epigenetic modulators of gene expression. RaNA has four lead programs in various stages of preclinical development and can progre...
Share this:
RaNA Therapeutics
RaNA Therapeutics is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 10:15 am. Room Hearst.
Tuesday, January 8 at 10:15 am. Room Hearst.
RaNA discovers and develops highly selective epigenetic modulators of gene expression. RaNA has four lead programs in various stages of preclinical development and can progress from sequence identification in our database to in vivo data in an average of 12 weeks. The company has raised a $20.7M series A financing.
Visit: http://ranarx.com
Biotech Showcase™ 2013
Rapid Diagnostek, Inc.
Country: United States
Country: United States
Rapid Diagnostek Inc.has developed a patented, inexpensive, easy to use sensor appropriate for detecting bacteria, viruses, spores and disease biomarkers. Markets of opportuni...
Share this:
Rapid Diagnostek, Inc.
Rapid Diagnostek, Inc. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 11:00 am. Room Mission I.
Wednesday, January 9 at 11:00 am. Room Mission I.
Rapid Diagnostek Inc.has developed a patented, inexpensive, easy to use sensor appropriate for detecting bacteria, viruses, spores and disease biomarkers. Markets of opportunity include human and veterinary diagnostic, environmental, biohazard, bioterrorism, agricultural commodity, and food safety testing.
Visit: http://rdxi.com
Biotech Showcase™ 2013
Relmada Therapeutics
Country: United States
Country: United States
Relmada is developing novel versions of proven drug products and a new molecule that potentially address area’s of high unmet medical need in the treatment of pain. The Comp...
Share this:
Relmada Therapeutics
Relmada Therapeutics is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 1:45 pm. Room Hearst.
Tuesday, January 8 at 1:45 pm. Room Hearst.
Relmada is developing novel versions of proven drug products and a new molecule that potentially address area’s of high unmet medical need in the treatment of pain. The Company has a deep and diversified portfolio of four lead products at different stages of development.
Visit: http://www.relmada.com
Biotech Showcase™ 2013
ReNeuron Group plc
(LON:RENE)
Country: United Kingdom
(LON:RENE)
Country: United Kingdom
ReNeuron is a leading, clinical-stage stem cell biopharmaceutical company. Its primary objective is the development of novel stem cell therapies targeting areas of significant...
Share this:
ReNeuron Group plc
ReNeuron Group plc is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 10:30 am. Room Powell.
Tuesday, January 8 at 10:30 am. Room Powell.
ReNeuron is a leading, clinical-stage stem cell biopharmaceutical company. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
Visit: http://www.reneuron.com
Biotech Showcase™ 2013
Repros Therapeutics
(NASDAQ:RPRX)
Country: United States
(NASDAQ:RPRX)
Country: United States
Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
Share this:
Repros Therapeutics
Repros Therapeutics is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 9:30 am. Room Mission II.
Wednesday, January 9 at 9:30 am. Room Mission II.
Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
Visit: http://reprosrx.com
Biotech Showcase™ 2013
Resverlogix Corp.
(TSE:RVX)
Country: Canada
(TSE:RVX)
Country: Canada
Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-...
Share this:
Resverlogix Corp.
Resverlogix Corp. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 1:45 pm. Room Mission II.
Tuesday, January 8 at 1:45 pm. Room Mission II.
Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis, currently in a Phase 2b IVUS trial with Cleveland Clinic.
Visit: http://www.resverlogix.com
Biotech Showcase™ 2013
Retrophin
(OTCBB:RTRX)
Country: United States
(OTCBB:RTRX)
Country: United States
Retrophin is focused on discovering and developing treatments for rare and life-threatening diseases. Retrophin is currently developing treatments for Focal Segmental Glomerul...
Share this:
Retrophin
Retrophin is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 2:15 pm. Room Powell.
Wednesday, January 9 at 2:15 pm. Room Powell.
Retrophin is focused on discovering and developing treatments for rare and life-threatening diseases. Retrophin is currently developing treatments for Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases.
Visit: http://www.retrophin.com/
Biotech Showcase™ 2013
RhinoCyte, Inc.
Country: United States
Country: United States
RhinoCyte is proposing changing the treatment paradigm available for neurodegenerative disorders and diseases. These treatments have been palliative in nature acting to improv...
Share this:
RhinoCyte, Inc.
RhinoCyte, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 1:45 pm. Room Mission I.
Tuesday, January 8 at 1:45 pm. Room Mission I.
RhinoCyte is proposing changing the treatment paradigm available for neurodegenerative disorders and diseases. These treatments have been palliative in nature acting to improve only the symptomatic manifestations of the diseases. RhinoCyte’s technology has the potential to facilitate functional recovery in these patients.
Visit: http://www.rhinocyte.com/
Biotech Showcase™ 2013
Rhythm
Country: United States
Country: United States
melanocortin-4 receptor agonist is in Phase 1 clinical trials for the treatment of obesity and diabetes; and RM-131, a small-peptide ghrelin agonist, is in Phase 2 trials for ...
Share this:
Rhythm
Rhythm is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 2:45 pm. Room Hearst.
Wednesday, January 9 at 2:45 pm. Room Hearst.
melanocortin-4 receptor agonist is in Phase 1 clinical trials for the treatment of obesity and diabetes; and RM-131, a small-peptide ghrelin agonist, is in Phase 2 trials for the treatment of diabetic gastroparesis and other gastrointestinal functional disorders.
Visit: http://www.rhythmtx.com
Biotech Showcase™ 2013
RXi Pharmaceuticals, Corp.
(OTCBB:RXII)
Country: United States
(OTCBB:RXII)
Country: United States
RXi Pharmaceuticals is focused on the discovery and development of novel RNAi therapeutics to treat diseases that can be addressed with local delivery. RXi’s revolutionary r...
Share this:
RXi Pharmaceuticals, Corp.
RXi Pharmaceuticals, Corp. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 9:30 am. Room Mission II.
Tuesday, January 8 at 9:30 am. Room Mission II.
RXi Pharmaceuticals is focused on the discovery and development of novel RNAi therapeutics to treat diseases that can be addressed with local delivery. RXi’s revolutionary rxRNA® technology platform includes several different types of RNAi’s designed to circumvent delivery and tolerance issues associated with the development of traditional RNAi compounds.
Visit: http://rxipharma.com
Biotech Showcase™ 2013
SafeGenomics LLC
Country: United States
Country: United States
SafeGenomics is a consumer health company that empowers users by consolidating all their health information in one place and leverages the power of that health data to produce...
Share this:
SafeGenomics LLC
SafeGenomics LLC is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 2:45 pm. Room Mission I.
Tuesday, January 8 at 2:45 pm. Room Mission I.
SafeGenomics is a consumer health company that empowers users by consolidating all their health information in one place and leverages the power of that health data to produce better healthcare outcomes for individuals. The release of its core product (“Helix Hub”) incorporates and weighs genomics, health, and wellness inputs individually and collectively into individuals’ health equation, producing actionable and usable items for its consumers to apply in their daily lives.
Visit: http://safegenomics.com
Biotech Showcase™ 2013
SanBio, Inc.
Country: United States
Country: United States
SanBio is a clinical-stage CNS regenerative medicine company with a lead product in Phase-1/2. Indications include Stroke recovery, Tramatic Brain Injury, Retinitis Pigmentos...
Share this:
SanBio, Inc.
SanBio, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 11:30 am. Room Mission I.
Tuesday, January 8 at 11:30 am. Room Mission I.
SanBio is a clinical-stage CNS regenerative medicine company with a lead product in Phase-1/2. Indications include Stroke recovery, Tramatic Brain Injury, Retinitis Pigmentosa and dry AMD (CNS). SanBio's products are allogeneic adult stem cell products possesing critical advantage in commercialization. It is seeking a corporate partner for our CNS product.
Visit: http://www.san-bio.com
Biotech Showcase™ 2013
Savara
Country: United States
Country: United States
Savara Pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. The...
Share this:
Savara
Savara is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 11:15 am. Room Hearst.
Tuesday, January 8 at 11:15 am. Room Hearst.
Savara Pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. The company’s lead product, AeroVanc (vancomycin hydrochloride inhalation powder), is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis.
Visit: http://www.savarapharma.com
Biotech Showcase™ 2013
Second Genome
Country: United States
Country: United States
Second Genome brings microbiome science to the discovery and development of pharmaceutical products. Using its proprietary platform, the company has established a pipeline of ...
Share this:
Second Genome
Second Genome is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 11:45 am. Room Hearst.
Wednesday, January 9 at 11:45 am. Room Hearst.
Second Genome brings microbiome science to the discovery and development of pharmaceutical products. Using its proprietary platform, the company has established a pipeline of microbiome modulators that impact infection, immunity, and metabolic diseases.
Visit: http://www.secondgenome.com
Biotech Showcase™ 2013
Senesco Technologies, Inc
(OTCBB:SNTI)
Country: United States
(OTCBB:SNTI)
Country: United States
Senesco, a leader in eIF5A technology, is sponsoring a clinical study to evaluate its lead therapeutic candidate SNS01-T in multiple myeloma, diffuse large B-cell lymphoma and...
Share this:
Senesco Technologies, Inc
Senesco Technologies, Inc is scheduled to present at Biotech Showcase™ 2013
Monday , January 7 at 10:00 am. Room Mission II.
Monday , January 7 at 10:00 am. Room Mission II.
Senesco, a leader in eIF5A technology, is sponsoring a clinical study to evaluate its lead therapeutic candidate SNS01-T in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma. SNS01-T targets B-cell cancers and selectively induces apoptosis by modulating eukaryotic translation initiation factor 5A (eIF5A).
Visit: http://senesco.com
Biotech Showcase™ 2013
Sernova Corp.
(CVE:SVA)
Country: Canada
(CVE:SVA)
Country: Canada
Sernova is a clinical stage MedTech company committed to developing and commercializing products which benefit patients with chronic metabolic, neurological, and haematologica...
Share this:
Sernova Corp.
Sernova Corp. is scheduled to present at Biotech Showcase™ 2013
Monday , January 7 at 1:45 pm. Room Mission II.
Monday , January 7 at 1:45 pm. Room Mission II.
Sernova is a clinical stage MedTech company committed to developing and commercializing products which benefit patients with chronic metabolic, neurological, and haematological diseases. It is initiating clinical trials of its Cell Pouch(TM) to treat insulin-dependent diabetes based on it very compelling preclinical results in various cell transplantation models of diabetes.
Visit: http://www.sernova.com
Biotech Showcase™ 2013
Shenogen Pharma Group
Country: China
Country: China
Shenogen is focusing on developing innovative therapeutics against ER-α36, a novel estrogen receptor variant that mediates membrane initiated estrogen signaling and cell grow...
Share this:
Shenogen Pharma Group
Shenogen Pharma Group is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 10:15 am. Room Mission II.
Wednesday, January 9 at 10:15 am. Room Mission II.
Track: Track C
Country: China
Ownership: PRIVATE
Country: China
Ownership: PRIVATE
Shenogen is focusing on developing innovative therapeutics against ER-α36, a novel estrogen receptor variant that mediates membrane initiated estrogen signaling and cell growth. It has developed small molecules and humanized therapeutic antibodies inhibiting ER-α36. The first compound is being evaluated in phase Ib clinical trial in liver and breast cancer.
Visit: http://www.shenogen.com.cn/
Biotech Showcase™ 2013
Shire
(NASDAQ:SHPG)
Country: United States
(NASDAQ:SHPG)
Country: United States
Shire is a global specialty biopharmaceuticals company with operations in 28 countries and several medicines available in more than 45 countries, Shire has eight core products...
Share this:
Shire
Shire is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 2:15 pm. Room Powell.
Tuesday, January 8 at 2:15 pm. Room Powell.
Shire is a global specialty biopharmaceuticals company with operations in 28 countries and several medicines available in more than 45 countries, Shire has eight core products in the areas of Attention Deficient Hyperactivity Disorder, Gastrointestinal disease, Renal disease, and Genetic Disease.
Biotech Showcase™ 2013
Sigmoid Pharma
Country: Ireland
Country: Ireland
Sigmoid Pharma has developed two proprietary oral pharmaceutical formulation technologies known as LEDDS® (liquid/emulsion drug delivery system) and SmPill® (single-multiple...
Share this:
Sigmoid Pharma
Sigmoid Pharma is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 3:45 pm. Room Mission I.
Wednesday, January 9 at 3:45 pm. Room Mission I.
Sigmoid Pharma has developed two proprietary oral pharmaceutical formulation technologies known as LEDDS® (liquid/emulsion drug delivery system) and SmPill® (single-multiple pill) which it employs in developing its own products as well as those of partners.
Visit: http://www.sigmoidpharma.com
Biotech Showcase™ 2013
Single Cell Technology
Country: United States
Country: United States
Single Cell partners with biopharma’s to discover unusual antibodies. It is the only company to use NGS to massively sequence the cognate mRNA while simultaneously measuring...
Share this:
Single Cell Technology
Single Cell Technology is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 4:00 pm. Room Mission II.
Wednesday, January 9 at 4:00 pm. Room Mission II.
Single Cell partners with biopharma’s to discover unusual antibodies. It is the only company to use NGS to massively sequence the cognate mRNA while simultaneously measuring kinetics. By eliminating fusion we screen humans, mice, rats, dogs, rabbits, and soon goats, horses and cats. It is seeking Series A investors.
Biotech Showcase™ 2013
SiteOne
Country: United States
Country: United States
SITEONE, a Stanford University startup, is developing long-acting, non-narcotic pain medicines for acute and chronic pain management. IT is also advancing novel molecular dia...
Share this:
SiteOne
SiteOne is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 4:45 pm. Room Mission II.
Wednesday, January 9 at 4:45 pm. Room Mission II.
SITEONE, a Stanford University startup, is developing long-acting, non-narcotic pain medicines for acute and chronic pain management. IT is also advancing novel molecular diagnostics for locating pain generators - information that will more accurately guide treatment. Its therapeutic and imaging agents target sodium channels in pain-sensing nerves.
Biotech Showcase™ 2013
Solidus Biosciences, Inc.
Country: United States
Country: United States
Solidus' mission is to improve the process of new drug development by providing proprietary decision-enabling technology to enhance drug safety, efficiency, cost, and, thereby...
Share this:
Solidus Biosciences, Inc.
Solidus Biosciences, Inc. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 11:15 am. Room Mission I.
Wednesday, January 9 at 11:15 am. Room Mission I.
Solidus' mission is to improve the process of new drug development by providing proprietary decision-enabling technology to enhance drug safety, efficiency, cost, and, thereby, productivity from investment in new drug research and development.
Biotech Showcase™ 2013
SpectraScience, Inc.
(PINK:SCIE)
Country: United States
(PINK:SCIE)
Country: United States
SpectraScience is a biophotonic company. It uses the physical properties of light and its interaction with human tissue to diagnose certain epithelial cancers in vivo, in rea...
Share this:
SpectraScience, Inc.
SpectraScience, Inc. is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 2:15 pm. Room Mission II.
Wednesday, January 9 at 2:15 pm. Room Mission II.
SpectraScience is a biophotonic company. It uses the physical properties of light and its interaction with human tissue to diagnose certain epithelial cancers in vivo, in real time (approximately 1 second), at a cellular level. Its first commercial product, for colorectal cancer, has Sensitivity of 97% and NPV of 96%.
Biotech Showcase™ 2013
SteadyMed Therapeutics
Country: United States
Country: United States
SteadyMed is a drug delivery therapeutics company and leaders in the development and commercialization of prefilled, size efficient and disposable patch pump technology. Stead...
Share this:
SteadyMed Therapeutics
SteadyMed Therapeutics is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 4:15 pm. Room Hearst.
Wednesday, January 9 at 4:15 pm. Room Hearst.
SteadyMed is a drug delivery therapeutics company and leaders in the development and commercialization of prefilled, size efficient and disposable patch pump technology. SteadyMed is focused leveraging the sustainable cost and technological competitive advantages of its PatchPump® platform to create a family of products.
Visit: http://www.steadymed.com
Biotech Showcase™ 2013
Stellar Biotechnologies, Inc.
(OTCBB:SBOTF)
Country: United States
(OTCBB:SBOTF)
Country: United States
Stellar is an immuno-vaccine company and the world leader in sustainable manufacturing of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin), with commercial-scale supply of...
Share this:
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 9:00 am. Room Mission II.
Monday, January 7 at 9:00 am. Room Mission II.
Stellar is an immuno-vaccine company and the world leader in sustainable manufacturing of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin), with commercial-scale supply of GMP-grade KLH. KLH has a highly complex structure that makes it ideal for use in conjugation for vaccines and diagnostic products.
Biotech Showcase™ 2013
StemPar Sciences
Country: United States
Country: United States
StemPar is a preclinical-stage startup developing novel, first-in-class therapeutics that exploits the key vulnerabilities of cancer cell metabolism. Led by a leadership team ...
Share this:
StemPar Sciences
StemPar Sciences is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 9:00 am. Room Mission I.
Tuesday, January 8 at 9:00 am. Room Mission I.
StemPar is a preclinical-stage startup developing novel, first-in-class therapeutics that exploits the key vulnerabilities of cancer cell metabolism. Led by a leadership team with a track record of producing rapid, high-value returns for investors, the company is focusing initially on pancreatic, breast, and non-small cell lung cancers.
Visit: http://stempar.com/
Biotech Showcase™ 2013
Sucampo Pharmaceuticals, Inc.
(NASDAQ:SCMP)
Country: United States
(NASDAQ:SCMP)
Country: United States
Sucampo is a global pharmaceutical company focused on innovative research, discovery development and commercialization of proprietary drugs based on prostones. Prostones have...
Share this:
Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 11:30 am. Room Mission II.
Tuesday, January 8 at 11:30 am. Room Mission II.
Sucampo is a global pharmaceutical company focused on innovative research, discovery development and commercialization of proprietary drugs based on prostones. Prostones have emerged as promised compounds with unique phyisiological activities and can be targeted for the treatment of unmet or under-served medical needs.
Visit: http://sucampo.com
Biotech Showcase™ 2013
Susavion Biosciences
Country: United States
Country: United States
Susavion has a platform to identify novel peptidic drugs that trigger activation of several types of immune effector cells. Susavion’s current focus is on cancer and infecti...
Share this:
Susavion Biosciences
Susavion Biosciences is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 4:00 pm. Room Hearst.
Tuesday, January 8 at 4:00 pm. Room Hearst.
Susavion has a platform to identify novel peptidic drugs that trigger activation of several types of immune effector cells. Susavion’s current focus is on cancer and infectious diseases which suppress the immune system, allowing disease progression. Susavion’s products provide a novel approach to activate the immune system.
Visit: http://www.susavion.com
Biotech Showcase™ 2013
Sutro Biopharma
Country: United States
Country: United States
Sutro Biopharma, is developing a new generation of multi-functional antibody drug conjugate combination therapeutics and bifunctional antibody-based therapeutics for targeted ...
Share this:
Sutro Biopharma
Sutro Biopharma is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 9:15 am. Room Mission I.
Wednesday, January 9 at 9:15 am. Room Mission I.
Sutro Biopharma, is developing a new generation of multi-functional antibody drug conjugate combination therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies.
Visit: http://www.sutrobio.com/
Biotech Showcase™ 2013
SuviCa, Inc.
Country: United States
Country: United States
SuviCa, Inc. is focused on the discovery and development of small molecules targeting the ribosome and steps during protein synthesis for the treatment of cancer. Suvica’s ...
Share this:
SuviCa, Inc.
SuviCa, Inc. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 2:30 pm. Room Mission I.
Monday, January 7 at 2:30 pm. Room Mission I.
SuviCa, Inc. is focused on the discovery and development of small molecules targeting the ribosome and steps during protein synthesis for the treatment of cancer. Suvica’s lead compounds show activity as single agents and in combination with standard therapies in models of Melanoma, Head and Neck Cancer, Glioblastoma, and Non-Small Cell Lung cancer.
Visit: http://www.suvica.com
Biotech Showcase™ 2013
TELORMEDIX SA
Country: Switzerland
Country: Switzerland
Telormedix focuses on Toll Like Receptor 7 as a therapeutic target for the development of both agonists and antagonists compounds. Its most advanced program is in phase 1/2 fo...
Share this:
TELORMEDIX SA
TELORMEDIX SA is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 11:30 am. Room Hearst.
Wednesday, January 9 at 11:30 am. Room Hearst.
Telormedix focuses on Toll Like Receptor 7 as a therapeutic target for the development of both agonists and antagonists compounds. Its most advanced program is in phase 1/2 for the treatment of bladder cancer. Its second product proof of concept in skin and bladder cancer has been completed.
Visit: http://www.telormedix.com
Biotech Showcase™ 2013
TheraKine, Ltd.
Country: United States
Country: United States
TheraKine has developed a sustained release delivery platform for the local delivery of biologic agents and small molecules. Its tunable, sustained-release technologies allow...
Share this:
TheraKine, Ltd.
TheraKine, Ltd. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 11:30 am. Room Hearst.
Monday, January 7 at 11:30 am. Room Hearst.
TheraKine has developed a sustained release delivery platform for the local delivery of biologic agents and small molecules. Its tunable, sustained-release technologies allows linear release of drug products with durations from weeks to months.
Visit: http://www.therakine.com/
Biotech Showcase™ 2013
TheraVida
Country: United States
Country: United States
TheraVida is focused on improving the clinical benefits of existing drugs and NCEs by reducing major dose-limiting side effects, and also increasing efficacy. TheraVida has pr...
Share this:
TheraVida
TheraVida is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 3:45 pm. Room Hearst.
Tuesday, January 8 at 3:45 pm. Room Hearst.
TheraVida is focused on improving the clinical benefits of existing drugs and NCEs by reducing major dose-limiting side effects, and also increasing efficacy. TheraVida has programs in urology (overactive bladder) and CNS (depression and ADHD). TheraVida has a core technology based on fixed-dose drug combinations.
Visit: http://www.theravida.com
Biotech Showcase™ 2013
Thetis Pharmaceuticals LLC
Country: United States
Country: United States
Thetis is developing innovative cardio-metabolic prescription drugs in the Omega-3 arena. Thetis has developed a broad patent portfolio covering new molecular entities in mult...
Share this:
Thetis Pharmaceuticals LLC
Thetis Pharmaceuticals LLC is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 2:30 pm. Room Mission I.
Tuesday, January 8 at 2:30 pm. Room Mission I.
Thetis is developing innovative cardio-metabolic prescription drugs in the Omega-3 arena. Thetis has developed a broad patent portfolio covering new molecular entities in multiple therapeutic areas, with composition of matter, method of use and manufacturing claims. The patent portfolio also covers physical combinations with other drugs including statins.
Visit: http://thetispharma.com/
Biotech Showcase™ 2013
TIGENIX NV
(EBR:TIG)
Country: Belgium
(EBR:TIG)
Country: Belgium
TiGenix is focused on novel cell therapeutic products. The merger with Cellerix in 2011 secured long term growth through a clinical stage pipeline of allogeneic adult Mesenchy...
Share this:
TIGENIX NV
TIGENIX NV is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 2:45 pm. Room Powell.
Tuesday, January 8 at 2:45 pm. Room Powell.
TiGenix is focused on novel cell therapeutic products. The merger with Cellerix in 2011 secured long term growth through a clinical stage pipeline of allogeneic adult Mesenchymal Stem Cells (MSCs). TiGenix is now a fully integrated company with commercial infrastructure in Western Europe.
Visit: http://www.tigenix.com
Biotech Showcase™ 2013
TissueGene
Country: United States
Country: United States
TissueGene offers a non-invasive treatment to restore cartilage in patients suffering from osteoarthritis of the knee. TG-C has the ability to relieve knee pain and improve kn...
Share this:
TissueGene
TissueGene is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 3:00 pm. Room Hearst.
Tuesday, January 8 at 3:00 pm. Room Hearst.
TissueGene offers a non-invasive treatment to restore cartilage in patients suffering from osteoarthritis of the knee. TG-C has the ability to relieve knee pain and improve knee function by not only treating arthritic symptoms but the disease itself.
Visit: http://www.tissuegene.com
Biotech Showcase™ 2013
TVAX Biomedical
Country: United States
Country: United States
TVAX is advancing a Phase 2 stage brain cancer program. Its unique therapy combines personalized cancer cell vaccination and “killer” T cell treatment without undesirable ...
Share this:
TVAX Biomedical
TVAX Biomedical is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 10:30 am. Room Hearst.
Wednesday, January 9 at 10:30 am. Room Hearst.
Track: Track A
Country: United States
Ownership: PRIVATE
Country: United States
Ownership: PRIVATE
TVAX is advancing a Phase 2 stage brain cancer program. Its unique therapy combines personalized cancer cell vaccination and “killer” T cell treatment without undesirable side effects. TVAX is the first and currently only company in the world to combine these two approaches into one potent treatment platform.
Biotech Showcase™ 2013
uniQure B.V.
Country: Netherlands
Country: Netherlands
uniQure’s lead product, Glybera, for the treatment of lipoprotein lipase deficiency was approved by the European Commission in November, 2012. Glybera is the first gene the...
Share this:
uniQure B.V.
uniQure B.V. is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 10:15 A.M.. Room Hearst.
Monday, January 7 at 10:15 A.M.. Room Hearst.
uniQure’s lead product, Glybera, for the treatment of lipoprotein lipase deficiency was approved by the European Commission in November, 2012. Glybera is the first gene therapy approved in the Western world. Its pipeline includes gene therapies: for hemophilia B, acute intermittent porphyria, Parkinson’s disease and Sanfilippo B.
Visit: http://www.uniqure.com
Biotech Showcase™ 2013
Valley Fever Solutions
Country: United States
Country: United States
Valley Fever Solutions expects to complete Phase II trials for Nikkomycin Z ("Nik Z") in 2013, moving NikZ towards approval for Valley Fever as a first indication. Nik Z" is ...
Share this:
Valley Fever Solutions
Valley Fever Solutions is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 2:30 pm. Room Hearst.
Wednesday, January 9 at 2:30 pm. Room Hearst.
Valley Fever Solutions expects to complete Phase II trials for Nikkomycin Z ("Nik Z") in 2013, moving NikZ towards approval for Valley Fever as a first indication. Nik Z" is first of a new class of antifungals, fungicidal for Valley Fever (Coccidioidomycosis, "cocci"), with expected efficacy against other fungi.
Biotech Showcase™ 2013
Vapogenix
Country: United States
Country: United States
Vapogenix is creating a new class of analgesics based on formulated volatile anesthetics to treat localized pain without the systemic side effects of existing drugs. Its fir...
Share this:
Vapogenix
Vapogenix is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 10:30 am. Room Hearst.
Tuesday, January 8 at 10:30 am. Room Hearst.
Vapogenix is creating a new class of analgesics based on formulated volatile anesthetics to treat localized pain without the systemic side effects of existing drugs. Its first product is a quick acting topical analgesic that is substantially faster than competing products. Successful development will enable development of longer duration products.
Visit: http://vapogenix.com
Biotech Showcase™ 2013
Venaxis, Inc. (formerly Aspen Biopharma)
(NASDAQ:APPY)
Country: United States
(NASDAQ:APPY)
Country: United States
Venaxisis an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test. The unique appendicitis test has proj...
Share this:
Venaxis, Inc. (formerly Aspen Biopharma)
Venaxis, Inc. (formerly Aspen Biopharma) is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 4:15 pm. Room Powell.
Monday, January 7 at 4:15 pm. Room Powell.
Venaxisis an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test. The unique appendicitis test has projected high sensitivity and negative predictive value and is designed to aide identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.
Biotech Showcase™ 2013
ViaCyte
Country: United States
Country: United States
ViaCyte is a preclinical company focused on diabetes. Its therapy is based on the differentiation of stem cells into pancreatic beta cell precursors, with subcutaneous implan...
Share this:
ViaCyte
ViaCyte is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 4:30 pm. Room Mission II.
Tuesday, January 8 at 4:30 pm. Room Mission II.
ViaCyte is a preclinical company focused on diabetes. Its therapy is based on the differentiation of stem cells into pancreatic beta cell precursors, with subcutaneous implantation in an encapsulation device. Its goal is to can free both Type 1 and Type 2 patients from insulin dependence on a long-term basis.
Visit: http://www.viacyte.com
Biotech Showcase™ 2013
viDA Therapeutics
Country: Canada
Country: Canada
viDA Therapeutics is a platform-based biotechnology company pursuing the discovery and development of novel, first-in-class drugs that inhibit the granzyme family of five seri...
Share this:
viDA Therapeutics
viDA Therapeutics is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 9:30 am. Room Hearst.
Wednesday, January 9 at 9:30 am. Room Hearst.
viDA Therapeutics is a platform-based biotechnology company pursuing the discovery and development of novel, first-in-class drugs that inhibit the granzyme family of five serine proteases.
Biotech Showcase™ 2013
Viropro
(PINK:VPRO)
Country: United States
(PINK:VPRO)
Country: United States
Viropro's principal objective is to become an international leader in the full service offering (cell line dev, process dev and cGMP) of high quality, competitively-priced bio...
Share this:
Viropro
Viropro is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 9:00 am. Room Mission II.
Tuesday, January 8 at 9:00 am. Room Mission II.
Viropro's principal objective is to become an international leader in the full service offering (cell line dev, process dev and cGMP) of high quality, competitively-priced biopharmaceutical products. It currently conducts operations through its subsidiaries Malaysia, California and Canada.
Visit: http://www.viropro.com
Biotech Showcase™ 2013
Virovek Incorporation
Country: United States
Country: United States
Virovek is a leader in adeno-associated virus (AAV) vector design, production, and purification. It has the world's most efficient large-scale AAV manufacturing system through...
Share this:
Virovek Incorporation
Virovek Incorporation is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 3:15 pm. Room Mission I.
Tuesday, January 8 at 3:15 pm. Room Mission I.
Virovek is a leader in adeno-associated virus (AAV) vector design, production, and purification. It has the world's most efficient large-scale AAV manufacturing system through our innovation and proprietary technologies. It is also actively developing cutting-edge suicide gene therapy methodologies in different viral vectors.
Visit: http://www.virovek.com
Biotech Showcase™ 2013
Vitatex
Country: United States
Country: United States
Employing unique technology to isolate invasive metastasis-initiating tumor cells in blood samples, Vitatex has developed tests that greatly improve prognosis, drug selection ...
Share this:
Vitatex
Vitatex is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 4:45 pm. Room Hearst.
Wednesday, January 9 at 4:45 pm. Room Hearst.
Employing unique technology to isolate invasive metastasis-initiating tumor cells in blood samples, Vitatex has developed tests that greatly improve prognosis, drug selection and treatment monitoring for cancer patients. With $4.6 million in NCI funding the company has generated compelling clinical data and is poised for full commercialization.
Visit: http://www.vitatex.com
Biotech Showcase™ 2013
Wellesley Pharmaceuticals
Country: United States
Country: United States
Wellesley develops therapeutics for Nocturia, a condition that harms 2 billion people. Current OAB drugs can take months to reach efficacy and side effects cause 80% of users...
Share this:
Wellesley Pharmaceuticals
Wellesley Pharmaceuticals is scheduled to present at Biotech Showcase™ 2013
Wednesday, January 9 at 10:00 am. Room Mission I.
Wednesday, January 9 at 10:00 am. Room Mission I.
Track: Track B
Country: United States
Ownership: PRIVATE
Country: United States
Ownership: PRIVATE
Wellesley develops therapeutics for Nocturia, a condition that harms 2 billion people. Current OAB drugs can take months to reach efficacy and side effects cause 80% of users give up within 2 months. In animal & informal human tests, Wellesley’ drug yielded strong results on day 1 without side effects.
Biotech Showcase™ 2013
Zalicus
(NASDAQ:ZLCS)
Country: United States
(NASDAQ:ZLCS)
Country: United States
Zalicus discovers and develops novel treatments for patients suffering from pain. It has a portfolio of proprietary clinical-stage product candidates targeting pain. It has e...
Share this:
Zalicus
Zalicus is scheduled to present at Biotech Showcase™ 2013
Monday, January 7 at 9:30 am. Room Powell.
Monday, January 7 at 9:30 am. Room Powell.
Zalicus discovers and develops novel treatments for patients suffering from pain. It has a portfolio of proprietary clinical-stage product candidates targeting pain. It has entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies.
Visit: http://zalicus.com
Biotech Showcase™ 2013
Zymeworks Inc.
Country: Canada
Country: Canada
Zymeworks develops best-in-class bi-specific antibody and protein therapeutics designed using proprietary molecular simulation technology with high performance computing to de...
Share this:
Zymeworks Inc.
Zymeworks Inc. is scheduled to present at Biotech Showcase™ 2013
Tuesday, January 8 at 9:15 am. Room Hearst.
Tuesday, January 8 at 9:15 am. Room Hearst.
Zymeworks develops best-in-class bi-specific antibody and protein therapeutics designed using proprietary molecular simulation technology with high performance computing to design and optimize protein therapeutics.
Visit: http://zymeworks.com
Biotech Showcase™ 2013
